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ABBREVIATIONS 
 
AP-1 Activator protein 1 
ApoB100 Apolipoprotein B-100 
ApoE Apolipoprotein E 
CCL2 c-motif chemokine ligand 2 
CCR2 c-motif chemokine receptor 2 
CD Cluster of differentiation 
CX3CR1 C-X3-C motif chemokine receptor 1 
DAMP Damage/Danger-associated molecular pattern 
HF diet High fat diet 
HMGB1 High mobility group box 1 protein 
IFN-γ Interferon gamma 
IL-1 / 6 /12 Interleukin 1 / 6 / 12 
IRF Interferon regulatory factor 
LAA Large-artery atherosclerosis 
LDL Low-density lipoprotein 
Ly6C Lymphocyte antigen 6 complex 
M-CSF Macrophage colony-stimulating factor 
MMP Matrix metalloproteases 
MRI Magnetic resonance imaging 
NFκB 
Nuclear factor ‘kappa-light-chain-enhancer’ 
for activated B cells 
OxLDL Oxidized low-density lipoprotein 
PRR Pattern recognition receptor 
Rag 1 / 2 Recombination activating gene 1 /2 
RAGE Receptor for advanced glycation endproducts 
SMC Smooth muscle cell 
SNS Sympathetic nervous system 
TNF-α Tumor necrosis factor alpha 
tPA Tissue plasminogen activator 
VCAM-1 Vascular cell adhesion molecule 1 
VLA-4 Very late antigen 4 
VLDL Very low-density lipoprotein 
WT Wild type 
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1 INTRODUCTION  
1.1 Stroke 
A stroke is caused by the interruption of the blood supply to the brain, usually because a blood vessel 
bursts (hemorrhagic) or is blocked by a clot (ischemic). Approximately 85 % of all strokes are 
ischemic and 15 % are hemorrhagic. This event cuts off oxygen and nutrients supply, causing damage 
to the brain tissue. The most common symptom of a stroke is sudden weakness or numbness of the 
face, arm or leg, most often on one side of the body. Other symptoms include: confusion, difficulty in 
speaking or understanding speech; difficulty seeing with one or both eyes; difficulty walking, 
dizziness, loss of balance or coordination; severe headache (hemorrhagic) with no known cause; 
fainting or unconsciousness. 
The effects of a stroke depend on which part of the brain is injured and how severely it is affected. 
(Definition by World Health Organization, http://www.who.int/topics/cerebrovascular_accident/en/). 
1.1.1 Epidemiology 
In 2010, the absolute number of first-ever strokes worldwide was 16.9 million, causing a total of 
approximately 5.9 million deaths1. In the 2017 update of the heart disease and stroke statistics 2, stroke 
ranks No. 5 among all causes of death behind heart diseases, cancer, chronic lower respiratory disease 
and unintentional injuries. Stroke has a global epidemiology; about 85 % of all stroke deaths are 
registered in low- and middle income countries3. Moreover, the age-standardized incidence of stroke 
significantly decreased in high-income countries, whereas it is still increasing in low- and middle-
income countries4. In 2010, stroke was the third most common cause of disability-adjusted life-years 
(102 million)5. Compared to 1990 this is a significant increase and prognosis is still rising. In addition, 
5.2 million strokes occurred in children (aged <20 years old) and young to mid-aged adults (<64 
years). In Europe, the total annual costs imposed by stroke patients were estimated to be € 64.1 billion 
in 20106. Recurrent stroke events are an additional burden. In 2002, a study from South Carolina 
started which (USA) showed a recurrence rate of 5 % after 6 months, 8 % after 1 year and 18,1 % after 
4 years7. Recurrent stroke is highly associated with greater numbers of risk factors and higher 
incidence of large-vessel atherosclerosis than the first stroke8,9. The stroke incidence and costs will 
further increase due to aging of the population10. 
1.1.2 Etiology 
The most common forms of stroke are ischemic stroke and the hemorrhagic stroke. About 15 % are 
hemorrhagic, initialized by a ruptured vessel and resulting in extravasation of blood. Hemorrhagic 
stroke is sub classified in intracranial hemorrhagic (ca. 10 %) and subarachnoid hemorrhagic stroke 
(ca. 5 %). Of all strokes 85 % are classified as ischemic11. An ischemic stroke can be the result of an 
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embolus or a local thrombus, which can cause a narrowing or even occlusion of a supply artery of the 
brain. Based on Trial of Org 10172 in Acute Stroke Treatment (TOAST) criteria12 five different types 
of ischemic stroke can be classified: 1) large-vessel disease, 2) cardioembolism, 3) small-vessel 
disease, 4) stroke of other determined etiology, and 5) stroke of undetermined etiology (Fig. 1). For 
large-vessel disease, one of the supplying brain arteries is occluded by lipid-laden atherosclerotic 
plaque or narrowed by a severe stenosis. Cardioembolism is induced in much the same way like 
atherothrombosis, however the blood clot originates from the heart, for example as a result of 
supraventricular arrhythmias due to atrial fibrillation. Small-vessel derived strokes are classically 
small (<1.5cm) and depending on the location within brain, usually lacunar syndromes. 
 
Figure 1. Ischemic stroke subclassification (Modified from Gomes J. and Wachsman A.M. Handbook of Clinical Nutrition 
and Stroke, Springer Science 2013). 
1.1.3 Therapy of ischemic stroke 
Although the medical and economic burden of stroke is enormous, thrombolysis with tissue 
plasminogen activator (tPA)13 and mechanical vascular recanalization14,15 are currently the only 
clinically approved therapies for ischemic stroke. Additionally, well known limitations and risks 
including a short time window, coagulation abnormalities, intracranial hemorrhage and further 
contraindications, make these therapeutic options only accessible for a small percentage of stroke 
patients10,16. Secondary prevention after acute treatment against recurrent ischemic events is provided 
with antiplatelet drugs, for example aspirin, statins against hypercholesterolemia and anticoagulants. 
Moreover, mechanical endarterectomy for symptomatic carotid artery stenosis is an option. However, 
prognosis for stroke patients remains poor and necessity for effective stroke treatment remains urgent. 
To overcome this lack of treatments, translational stroke research mainly focused on neuroprotective 
approaches in the acute phase after stroke for the last two decades. In total, more than 1,000 possible 
neuroprotective agents and compounds have been tested, in vitro and in animal models. Although 
promising results were achieved in this experimental setup, the approximately 50 compounds reaching 
large-vessel disease (12.9 %)
cardioembolism (36,5 %)
small-vessel disease (18,4 %)
other determined causes (6 %)
undetermined causes (26,2 %)
11 
 
clinical trials did not show any improvement in the patient10,17. Possible reasons for the failure are of 
either methodological or translational nature. The inappropriate selection of experimental animals in 
terms of physiology, genetic background, sex and age play an important role. Additionally, design of 
the study including dosage of drugs and administration route are as pivotal as appropriate statistics of 
experimental studies18. In particular, this phenomenon was discussed as “translational roadblock” in 
stroke research and started to lead scientists away from acute neuroprotective treatment towards 
subsequent processes in the immune system and associated phenomena like comorbidities and tissue 
regeneration. 
1.1.4 The systemic immune response after stroke 
Inflammation is an essential element of stroke pathology. Ischemia-induced brain tissue damage 
activates astrocytes and local immune cells like microglia19. Continuous crosstalk of local immune 
cells in the brain and the increased expression of adhesion molecules and chemokines lead to 
recruitment of peripheral immune cells. Inflammatory signaling is instrumental in all stages after 
ischemia in brain and plays an important role from early damage associated events until the late 
processes underlying post-ischemic tissue repair20,21,22. 
Stroke not only inflicts inflammatory processes in the brain, it also induces sterile immune responses 
systemically. Release of endogenous alarmins from necrotic cerebral cells is one initiator of peripheral 
immune responses. Alarmins – also referred to as damage/danger-associated molecular patterns 
(DAMPs) – represent a plethora of different molecules. The heterogeneous group of alarmins includes 
various proteins but also DNA and ATP, which are all passively released from necrotic tissue. 
An example for a prototypic alarmin is the high mobility group box 1 protein (HMGB1). HMGB1 is 
the most abundant non-histonic nuclear protein and a highly conserved molecule23. Under healthy 
conditions HMGB1 binds to the minor groove of linear DNA and assists the binding of transcription 
factors24. However, HMGB1 is immediately released from the nucleus to the extracellular space when 
cells undergo necrotic cell death. Once released, the reduction/oxidation-state of HMGB1 is 
detrimental for its function. Oxidation of the cysteines on amino acid position 23, 45 and 106 makes 
the protein either chemotactic (=all-thiol HMGB1)25, cytokine-inducing (=disulfide HMGB1)26 or as 
fully oxidized protein (=sulfonyl HMGB1)27 even resolving the inflammation. Disulfide HMGB1, 
which we found predominately in murine and human stroke plasma 24 to 48 h after ischemia28,29, has a 
high affinity for pattern recognition receptors (PRRs)21. In the repertoire of PRRs the receptor for 
advanced glycation endproducts (RAGE) and toll-like receptors 2 and 4 (TLR2 and 4) are the most 
abundant binding partners30. HMGB1-RAGE, -TLR2 or -TLR4 interactions immediately activate pro-
inflammatory intracellular signaling cascades. Downstream, the cascade NFκB translocates to the 
nucleus and initiates expression of pro-inflammatory cytokines such as IL-1β, IL-6, TNF-α and 
additional HMGB1. 
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Figure 2. Different stages of peripheral immune competence after stroke. Stroke is an initial event for a complex sterile 
peripheral immune cascade. Acute (over)activation of the immune system is followed by a subacute immunosuppression 
phase, which provides ground for infections like pneumonia. Interestingly, in the chronic phase the immune competence 
strengthens again and stays in a state of chronic low-grade inflammation. 
Once alarmins reach the blood stream they induce not only inflammation in brain but a pronounced 
peripheral immune response. This peripheral immune response is a multiphasic cascade including an 
early inflammatory activation phase followed by subacute immunosuppression and a chronic low-
grade inflammation (Figure 2).  
The systemic acute inflammatory phase is characterized by a fast and pronounced reaction to the brain 
damage. High levels of pro-inflammatory cytokines such as IL-1, IL-6 and TNF-α are present in the 
plasma of mice and stroke patients already hours after stroke28. Additionally, stroke-induced 
sympathetic innervation activates bone marrow and induces emigration of myeloid cells into 
circulation. We and others31 found decreased numbers of myeloid cells in bone marrow already 24h 
after stroke. These bone marrow-derived cells migrate to the spleen29, where expression levels of TNF-
α and IL-6 are highly elevated32. Moreover, splenic monocytic cells provide high levels of major 
histocompatibility complex class II (MHCII). Those protein complexes provide antigen-information 
for splenic T and B cells initiating the adaptive immune response. 
The stage of (over)activation of the peripheral immune response is followed by subacute 
immunosuppression. A well-established concept for secondary immunosuppression is a sympathetic 
activation and a catecholamine-mediated defect33 leading to massive T cell death. This suppressive 
phenomenon provides space for secondary comorbidities, like pneumonia and urinary tract infections, 
which are difficult to control and cause death after cerebral ischemia34. Blockage of beta-
adrenoreceptors in experimental stroke showed a drastic reduction of bacterial infections and 
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subsequently, reduction of mortality in mice33. Another current concept for immunosuppression is an 
“exhausted phenotype” presented by immune cells. This phenotype is defined by a reduced cytokine 
production and a decrease in MHCII expression. Moreover, severe lymphoid cell death can be found 
in spleen, blood and thymus. Herein, the detailed mechanisms are still under investigation21.  
For the following chronic phase (> 10 days) after cerebral ischemia, recent evidences from my 
work29,35 as well as publications from other research groups36 suggest again immunological changes 
(Figure 2). Severe stroke induces long-term alteration of the immune system due to high levels of 
HMGB1 and cytokines such as IL-6. These were also found in stroke patients up to one year after the 
initial ischemic event36. In the context of stroke recurrence and common inflammatory comorbidities 
such as atherosclerosis, this provides a whole new perspective for stroke patient treatment.  
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1.2 Atherosclerosis 
Atherosclerosis is the main cause of vascular diseases including coronary artery disease and 
cerebrovascular events. It slowly progresses in lesion formation and luminal narrowing of arteries. The 
underlying pathology is a complex process involving a chronic inflammatory state of the arterial wall 
at predilection sites with blood flow turbulences such as arterial branches37. Consequently, plaque 
rupture and thrombosis are the most common causes leading to peripheral artery disease, acute 
coronary syndrome, and stroke38.  
1.2.1 Pathology 
The initial event in atherogenesis is a dysfunction in the vascular endothelium, structural alterations 
and surface presentation of scavenger receptors and proteoglycans39. These receptors lead to an 
accumulation of very low and low-density lipoproteins (VLDL, LDL) in the sub endothelial space. 
Moreover, binding of circulating cholesterol via apolipoprotein B100 (ApoB-100, containing LDL) to 
the proteoglycans has a key role of intimal retention. Subsequently, this leads to oxidative 
modification of the lipoproteins via reactive oxygen species and enzymes such as myeloperoxidase38. 
Oxidized LDL (oxLDL) initiates two critical changes in the vascular micro-milieu. First, it inhibits the 
production of endogenous nitric oxide, an important mediator of vasodilation40. Second, oxLDL 
activates the expression of adhesion molecules and chemokines by endothelial cells via multiple 
receptors such as the lectin-like oxidized low-density lipoprotein receptor-141 and PRRs. The 
amplified expression of adhesion molecules drives the intimal infiltration of immune cells. 
Consequently, this sequence of events results in an early stage of fatty streak lesions which mainly 
consist of monocytes and macrophages accumulating intracellular lipids known as foam cells. 
Continuous accumulation of apoptotic cells and cholesterol crystals induces the formation of a 
necrotic core (Figure 3). In this stage, lesions are covered by a fibrous cap, composed of smooth 
muscle cells (SMCs) and collagen structures42. Increased secretion of matrix metalloproteases and 
replacement of SMCs in the fibrous cap with macrophages leads to the thinning of the fibrous cap. 
Ultimately, these morphological changes in the composition of the plaque increase the vulnerability 
for plaque ruptures43-45. 
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Figure 3. Stages in the development of atherosclerotic lesions (adapted from Libby P and Hansson GK, 2011 Nature). 
a. Under healthy conditions there are three arterial layers, the intima, media and adventitia. The intima has direct contact with 
the blood via a monolayer of endothelial cells. The media is a complex extracellular matrix which embeds SMCs. The outer 
layer, adventitia, inhabits mast cells and fibroblasts but also contains nerve endings and supplying microvessels. b. The 
initiation of atherosclerosis include adhesion of blood-derived leukocytes to the activated endothelium and migration to the 
intima; maturation and proliferation of monocytes/macrophages and the uptake of lipids drive the atheroprogression further 
forward. c. Migration of SMCs from the media to the intima and production of matrix macromolecules such as collagen are 
involved in further lesion growth. Macrophages and SMCs can undergo apoptosis in advanced lesions and debris derived 
from dead cells can accumulate in the lesion center as a necrotic core. d. Thrombosis can arise when a plaque ruptures. The 
fracture of the fibrous cap enables the contact of blood coagulation components and tissue factor from the plaque. The 
thrombus can occlude a vessel leading to ischemia of the posterior area.  
1.2.2 The role of the immune system in atheroprogression 
Atherosclerosis is an inflammatory disease which is correlated to hyperlipidemia46,47. The immune 
system plays a major role in atherogenesis. The endothelium of healthy and atherosclerotic vessels 
expresses PRR, including Toll-like receptors and the receptor for RAGE. A broad spectrum of ligands 
can bind to PRRs. Ligation of modified or oxidized LDL to PRRs activates the pro-inflammatory 
signal pathways. Most abundant transcription factors in this inflammatory response43 are NFκB, IRF 
and AP-1. They mediate the expression of a series of genes encoding pro-inflammatory mediators 
such as cytokines and chemokines. Studies with PRR or intracellular signaling knockout mice showed 
altered atheroprogression compared to wildtype mice48,49. In addition to LDL, HMGB1 activates the 
endothelium as well and induces thereby the secretion of pro-inflammatory mediators50. 
These mediators can then subsequently attract circulating immune cells to the vascular lesions. 
Amongst others, chemokines such as the CC-chemokine ligand 2 (CCL2) play an important role in the 
recruitment and migration of monocytes into the vessel wall. Circulating monocytes express the 
receptor for CC-chemokine 2 (CCR2) on their membrane. Absence of either CCL2 or a knockout for 
its receptor CC-chemokine receptor 2 (CCR2) showed a decrease in early atheroprogression51. The 
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CCR2-CCL2 interaction is not only known to play a role in atheroprogression but is also a key driver 
of immune cell migration to the ischemic brain52. 
Moreover, the activated endothelium expresses membrane-bound adhesion molecules such as vascular 
cell adhesion molecule 1 (VCAM1) and selectins50,53. On the other side, immune cells express the very 
late antigen-4 (VLA-4) which is the most abundant ligand for VCAM154. In the initiation phase of 
atherosclerosis this interaction plays an important role. Adhesion molecule-immune cell interactions 
enable myeloid and lymphoid immune cells to enter the arterial wall (Figure 4)55,56.  
The majority of the early invading immune cells are monocytes which can in mice be characterized by 
the expression of lymphocyte antigen 6 complexes (Ly6C). Approximately 80 % of blood monocytes 
are expressing high levels of Ly6C (Ly6Chigh). Ly6Chigh monocytes are short-lived myeloid cells with 
pro-inflammatory functions. This subpopulation invades into inflamed tissue and differentiates into 
dendritic cells or macrophages56 (Figure 4). Ly6Chigh monocytes have been shown to egress the bone 
marrow via upregulation of CCR2 and to be attracted to inflammatory sites57. The other 20 % of 
monocytes are expressing only low levels of Ly6C (Ly6Clow). Moreover, this population expresses low 
levels of CCR2 but high levels of CX3CR1. They crawl along the luminal surface and are therefore 
referred to as patrolling58. Under the influence of inflammatory mediators, they extravasate and 
phagocytose pathogens.  
In contrast, human monocytes do not express Ly6C but are classified on the basis of CD14 and CD16 
expression. CD14highCD16neg monocytes are comparable to the murine Ly6Chigh monocyte population; 
they express high levels of CCR2 and are the most prevalent subset59. CD16+ monocytes comprise the 
counterpart to Ly6Clow monocytes. This subpopulation is called “non-classical monocytes” and shows 
patrolling behavior comparable to murine Ly6Clow monocytes58.  
The presence of costimulatory factors such as the macrophage colony-stimulating factor (M-CSF) 
initiates the differentiation of monocytes to macrophages60. In established atherosclerotic lesions 
resident macrophages have been shown to be mainly derived from proliferation but not de novo 
infiltration61. During the inflammation-driven atheroprogression the initial fatty streak lesion matures 
into an atherosclerotic plaque with necrotic core region (Figure 3). Continuous infiltration and 
proliferation of immune cells enhance the lesion. Moreover, death of macrophages and foam cells lead 
to the formation of a necrotic core. This region contains extracellular lipids, cholesterol crystals and 
cell debris and is surrounded by a fibrous cap which stabilizes the plaque56,62. Further progression of 
plaque pathology with increased secretion of matrix metalloproteinases and cytokines can cause 
thinning of the fibrous cap and lead to plaque destabilization63.  
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Figure 4. Monocyte recruitment and accumulation in plaques (modified from Moore, K.J. et al., Nature Reviews 
Immunology, 2013). The endothelial expression of chemokines (CCL2, CXCL1 etc.) and adhesion molecules (ICAM1, 
VCAM1) due to hyperlipidemia lead to monocyte recruitment into the early fatty streak formations. Especially 
Ly6Chighmonocytes infiltrate the plaque. Chemokine – chemokine receptor interactions, like CCL2 – CCR2 interactions, play 
a pivotal role in attracting monocytes to the lesions. Binding of endothelial adhesion molecules, especially ICAM1 and 
VCAM1, facilitate the arrest and finally extravasation of the cells into the intima. Monocytes can differentiate into 
macrophages and dendritic cells. Macrophages take up oxidized or naïve LDL via phagocytosis or scavenger receptor-
mediated pathways, resulting in the formation of foam cells. These foam cells secrete pro-inflammatory cytokines (IL-6, IL-
1β and TNF-α) and chemokines, amplifying the inflammatory response64,65.  
In addition, cells of the adaptive immune system are present in atherosclerotic lesions (Figure 3). 
Studies with adaptive immunity-deficient atherosclerotic mouse models demonstrated a substantial 
role of T and B cells in atherosclerosis. ApoE–/– mice crossed with lymphocyte-deficient mice lacking 
recombination-activating gene 1 or 2 (Rag1–/– or Rag2–/–) showed significantly less plaque 
progression, compared to ApoE–/– mice43,66. In contrast to monocytes, T cells are less abundant in 
atherosclerotic plaques and contribute mainly to the later stages of atheroprogression via secretion of 
pro-inflammatory mediators67,68. T cells recognize antigens in form of a complex of a foreign peptide 
bound to a MHC molecule. These antigens are presented by an antigen-presenting cell such as 
dendritic cells, which present antigens to T cells in the arterial wall69. However, the initial site of 
antigen presentation in atherosclerosis is unknown.  
CD4+ Thelper and CD8+ Tcytotoxic cells are found in human lesions, but Thelper cells dominate in numbers70. 
Similar to that, in ApoE–/– and LDLR–/– mice CD4+ T cells are the predominant subset in 
atherosclerotic lesions71. From human plaques it is known that T helper type 1 cells are drivers for 
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pathogenic effects72. Interferon gamma (IFN γ), signature cytokine of Th1 cells is correlated with 
higher MHC class II expression, enhanced protease and chemokine secretion, adhesion molecule 
presence and reduced fibrous cap formation43. On the other hand, IFN-γ deficiency leads to a reduction 
in lesion lipid accumulation and cellularity73. A similar effect was shown after inhibition of IL-12, 
another Th1-associated cytokine. While the early plaque progress decreased, there was no beneficial 
effect observed in established lesions74. In addition, deletion of Th1 transcription factor T-bet leads to 
significant reduction in lesion development43,75. Taken together, Th1 cells play a crucial role in the 
development of plaques. For the pro-inflammatory subset of Th17 cells the role in atherosclerosis is 
unclear. The signature cytokine IL-17 was detected in human atherosclerotic plaques76, however, the 
experimental approaches to date provided controversial results. The subset of regulatory T cells (Treg) 
shows atheroprotective effects in experimental studies. In this context, the most frequently described T 
cells are FoxP3+ T cells. They have been found in human and murine plaques in low numbers. 
Transfer of wildtype FoxP3+ T cells into atherosclerotic mice have been reported to be 
atheroprotective. They are known to produce IL-10 and transforming growth factor beta (TGF-
β), which both have atheroprotective effects in mouse models77.  
Studies on B cells have revealed controversial findings, showing atheroprotective as well as 
atheropromotive effects of B cells. One prominent example for a successful B cell-target treatment in 
experimental atherosclerosis was the depletion with an antibody against CD20 in atherosclerosis. This 
study demonstrated reduced lesion progression after depletion78. Moreover, this and other studies 
indicated that only B-2 and not B-1 (CD20+) cells are atheroprotective79,80,81. Taken together, the 
innate and adaptive immune responses are essential drivers for atherosclerotic development. Due to 
this fact, they also represent key targets for therapeutic approaches.  
 
1.2.3 Animal models of atherosclerosis 
An optimal animal model of atherosclerosis should develop various stages of the disease including 
fatty streaks, infiltration of immune cells, accumulation of foam cells, vulnerable and stable plaques as 
well as relevant complications such as calcification, ulceration, hemorrhage, plaque rupture, 
thrombosis, stenosis and the formation of aneurysms. Efforts are being made to develop animal 
models that replicate human atherosclerosis, however, each of the current animal models have some 
limitations82. 
Mice are the most widely used species for experimental studies on atherosclerosis. While large animal 
models have also been developed in rabbits, pigs and non-human primates, the ease of breeding and 
availability of genetic modifications in mice make them in most cases the favorite species of choice82. 
The two most frequently used models of genetically-induced atherosclerosis in mice are LDLR–/– and 
ApoE–/– mice. LDLR–/– mice have a knockout in the low density lipoprotein receptor, a membrane-
based receptor that recognizes apolipoprotein B100, which is placed in the phospholipid layer of 
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LDL83. These mice are mildly hypercholesterolemic on normal diet; however high-fat diet increases 
cholesterol levels remarkably. The severity of disease correlates significantly with blood cholesterol 
levels84,85. ApoE–/– mice have a knockout in the apolipoprotein E. In mice, there is only one ApoE 
isoform being essential for catabolizing lipoproteins and triglycerides. Plasma cholesterol is mostly 
carried on lipoprotein remnants and rather than LDL, the “offending” guy in human atherosclerosis82. 
From birth on ApoE–/– mice are hypercholesterolemic and develop spontaneous lesions under chow 
diet. When fed with a HF diet mice are severely hypercholesterolemic and develop more lesions86. 
Moreover, ApoE–/– mice develop severe, reproducible plaques with complex immune cell interactions 
within 8 weeks of HF diet87. Nevertheless, both models do not result in spontaneous plaque rupture, 
which is a limitation to further investigate consequences of atherosclerosis like myocardial infarction 
and stroke. To overcome these limitations, mouse models with unstable or even rupturing plaques 
have been developed. One possibility is a tandem stenosis of the common carotid artery in ApoE–/– 
mice fed with HF diet37. Another possibility is an additional gene modification. As an example, 
genetically modified ApoE–/– mice in which matrix metalloproteinases (MMP) expression of 
macrophages is upregulated show increased plaque instability88. And finally, the acceleration of plaque 
destabilization with chronic angiotensin II infusion also leads to a higher number of rupture sites in the 
fibrous cap89.  
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2 PROJECT DESIGN 
 
Acute brain lesions induce multiphasic alterations of the peripheral immune response comprising early 
activation and subsequent immunosuppression. In this project, we focused on soluble pro-
inflammatory mediators—referred to as alarmins—as potential mediators of post-stroke systemic 
inflammation. Alarmins are released from necrotic brain tissue and represent a potent mode of brain-
immune communication. Previous studies indicated a correlation between cerebral lesion volume and 
the extent of systemic immune alterations90. High mobility group box protein 1 (HMGB1) is a 
prototypic alarmin with strong pro-inflammatory functions. HMGB1 is passively secreted from the 
necrotic tissue after ischemia19,91. Levels of HMGB1 are reported to be elevated immediately after 
ischemic injury and to last for more than one year in stroke patients with severe stroke36. However, it 
was previously unknown whether post-stroke chronic inflammation has an impact on common 
inflammatory comorbidities. Atherosclerosis is not only one of the most prevalent prominent 
comorbidities in stroke patients but also a common etiology of recurrent stroke events8,9. 
Atherosclerosis has a complex inflammatory pathology initialized by a dysbalance in the lipid 
metabolism increasing the invasion of leukocytes to the arterial wall. This influx of immune cells 
results in a chronic pro-inflammatory milieu and subsequently in atherosclerotic plaques. Established 
atherosclerosis can lead to stenosis or to a plaque rupture causing a thrombus formation. Both can 
result in a blockage of brain-supplying arteries causing stroke. 
The hypothesis of this project was to test alarmin-mediated immune activation in experimental stroke 
and investigate the impact of this pathway on the progression of atherosclerosis after stroke induction. 
We used an experimental approach in established mouse models of stroke and atherosclerosis to 
investigate the following specific aims: 
 
A) How do alarmins affect the systemic immune interaction after experimental stroke? 
Manuscript 1 
B) What are possible signal pathways activating immune cells? 
Manuscript 1 & 2 
C) Does post-stroke systemic inflammation accelerate atherosclerosis progression? 
Manuscript 2 
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3 SUMMARIES 
3.1 Summary  
Stroke is one of the top 5 reasons for death in developed industrial countries. Approximately6 million 
people die due to stroke or its consequences. Moreover, stroke is the most frequent reason for 
disability in high-aged populations. Approximately 85 % of all strokes are ischemic and only 15 % are 
caused by intracerebral hemorrhage. The main reasons for ischemic stroke are a heart embolism, 
microangiopathies or a thromboembolic event in a distal brain artery caused by vessel stenosis 
(macroangiopathy). After stroke itself mortality is also influenced by infections in the subacute phase 
and recurrent ischemic events. The risk of a recurrent stroke event is up to 30 % within the first 5 years 
after stroke, about nine times the risk of stroke in general population 92. Especially macroangiopathy 
was correlated with the highest recurrence rate after the first stroke. 
After stroke, complex neuroimmunological alterations take place in the brain including the clearance 
of debris, building of a scar formation and a long-term regeneration of lost tissue. Moreover, a 
multiphasic immune cascade can be observed in the peripheral immune system. Within this project we 
found that passive secretion of alarmins—soluble mediators of neural cell death— can cause systemic 
immune alterations after ischemia. Alarmins implement a plethora of different molecules including 
different proteins, ATP and also DNA. In this context, the high mobility group box 1 protein 
(HMGB1) should be highlighted. A non-histonic nuclear protein which, once secreted to extracellular 
space, shows cytokine-like properties. HMGB1 is well known to interact with Pattern Recognition 
Receptors (PRR). In particular, it shows high affinity to the receptor of advanced glycation 
endproducts (RAGE). In general, PRRs are highly abundant on innate immune cells. The HMGB1-
RAGE interactions can activate intracellular signal cascades and thereby, activate these immune cells. 
An acute activation of the peripheral immune system can be detected almost immediately after stroke. 
Within the following days, the immune system breaks down and shows a subacute 
immunosuppression. We and others found strong evidences that the immune system modulates a 
chronic low grade inflammation after this suppressive phase. This can be seen in increased serum 
levels of pro-inflammatory markers such as HMGB1, IL-6 and TNF-α.  
The goal of my thesis was to investigate (1) how alarmins affect the systemic immune alterations after 
experimental stroke and (2) which signal pathways are involved in activation of immune cells. 
Moreover, we were interested in (3) how post-stroke immune alterations can affect one of the most 
common comorbidity of stroke, atherosclerosis. 
We were able to show increased HMGB1 serum concentrations almost immediately after experimental 
stroke in mice. In addition, a similar pattern of increased HMGB1 levels was found in stroke patients’ 
serum. A mass spectrometry analysis of murine serum after stroke demonstrated a change from a fully 
reduced state to the disulfide form of HMGB1 within 24 h after stroke. This highly reactive Redox 
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form of HMGB1 can be associated with the early activation of the innate and adaptive immune system 
in rodent and humans. Neutralization of circulating HMGB1 by monoclonal antibodies ameliorated 
pro-inflammatory cytokine expression in the spleen. The inflammatory response after stroke was also 
reflected by behavioral changes. Besides the focal deficits attributable to brain tissue loss, stroke mice 
were highly immobile and showed a disturbed circadian rhythm. These behavioral domains are 
commonly known to represent “cytokine-induced sickness behavior”. Correspondingly, neutralization 
of pro-inflammatory cytokines via antibody treatment improved overall activity and circadian rhythm 
disturbances. In RAGE knockout mice, behavioral deficits were also less prominent compared to WT 
stroke mice.  
In the subacute phase, we found an expansion of splenic innate immune cells and at the same time a 
decrease in adaptive immune cells counts. T cell counts were particularly decreased in blood and 
spleen during the subacute phase after stroke. Inhibition of HMGB1, knockout of RAGE and other 
PRRs resulted in a less immunosuppressive phenotype. 
In conclusion, immediately after stroke elevated levels of HMGB1 can be found in serum of mice and 
patients. These elevated levels of HMGB1 lead to an acute activation of the peripheral immune system 
by binding to PRRs such as RAGE. High levels of cytokines induce a behavioral phenotype known as 
“cytokine-induced sickness behavior” in mice, including immobility and disturbed circadian rhythm. 
Subsequently, the subacute phase is characterized by an exhausted immune system and a substantial 
reduction in T lymphocyte counts. 
 
After characterization of the acute and subacute phase after stroke, we focused our investigation on the 
chronic low-grade inflammation. We hypothesized that chronic systemic inflammation after stroke 
might affect the pathophysiology of inflammatory comorbidities of stroke patients such as 
atherosclerosis—one of the most common comorbidities in elderly patients and a main etiology of 
cerebrovascular events. Hence, we were interested in how post-stroke peripheral immune alterations 
can affect atherosclerosis. Therefore, we used a well-established atherosclerosis mouse model (ApoE–/–
). Mice were fed a high-fat diet (“western style diet”) to induce atherosclerosis. After 8 weeks of high-
fat diet, an experimental stroke was induced and we analyzed the atherosclerotic outcome one month 
after. We found increased plaque loads in aorta and aortic valve regions. Moreover, the myeloid cell 
numbers in atherosclerotic plaques were elevated. Histological analysis revealed fibrous cap thinning 
and evidences were found for plaque ruptures in ApoE–/–mice after stroke. De novo infiltration of 
myeloid cells was observed to be the key driver for increased myeloid cell counts in plaques. Already 
3 d after stroke, increased levels of CC-chemokine ligand 2 (CCL2) and its receptor (CCR2) were 
detectable in the aorta. Furthermore, we detected an activation of the vascular endothelium by soluble 
mediators. We found high levels of vascular adhesion molecule 1 (VCAM1) in the aortic region after 
stroke, using an in vivo MRI approach. VCAM1 plays a pivotal role in leukocyte extravasation into the 
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arterial wall. HMGB1 levels were still elevated in mice more than one month after stroke. At the same 
time, we observed murine and patients’ blood-derived monocytes still being activated. With an in vivo 
antibody-specific inhibition of HMGB1 and a systemic RAGE knockdown using small interfering 
RNA in mice, we were able to show that particularly the HMGB1-RAGE interaction played an 
important role in post-stroke atheroprogression. Besides post-stroke alarmins, we found a sympathetic 
activation of the bone marrow after stroke. Thus, we found an egress of CCR2+ monocytes from the 
bone marrow already 24 h after ischemia. Labeling myeloid cells with fluorescent nanocrystals 
enabled us to investigate trafficking of myeloid cells after stroke and revealed the translocation of 
myeloid cells to the spleen within 24h after stroke. In addition, we were able to inhibit cell egress from 
the bone marrow using adrenergic beta-receptor blockers. Lastly, we approached atheroprogression 
after stroke with a combined treatment approach (Beta-blocker + alarmin inhibitor) in order to dissect 
the differential contribution of the sympathetic stress response and alarmin-mediated pathways. These 
experiments revealed a synergistic effect of both cascades (stress and alarmins) with their blockage 
leading to significant amelioration of post-stroke atheroprogression. 
In summary, this project gave strong evidences that alarmins—passively secreted by dying neural 
cells—immediately activate the peripheral immunity after stroke (Figure 5). A multiphasic cascade is 
initiated which includes an acute immune (over)activation, followed by a subacute 
immunosuppression and a chronic low-grade inflammation. Furthermore, peripheral immune 
alterations have a substantial impact on the progression of atherosclerosis after stroke. We detected 
that stress response and alarmins synergize in post-stroke atheroprogression.  
Our studies were able to reveal some of the mechanisms involved in post-stroke atheroprogression and 
tested potential therapeutic targets. Nevertheless, further investigations are needed to fully understand 
the whole process in the complex interaction of post-stroke sterile inflammation, atheroprogression 
and recurrent ischemic events. 
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Figure 5. Schematic overview. Stroke-induced neural cell death leads to a release of alarmins, in particular HMGB1. At the 
same time, increased sympathetic nervous system (SNS) activation after stroke induces release of monocytes from the bone 
marrow. These cells can be found in the spleen where they get into contact with HMGB1 and other brain-derived alarmins 
and get activated. Activated monocytes interact with increased chemokine levels and adhesion molecules on the endothelium 
of vessels. This leads to a de novo migration of monocytes into established atherosclerotic plaques. Atheroprogression gets 
accelerated and plaques become more prone to rupture. This can ultimately induce recurrent ischemic cerebrovascular events. 
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3.2 Zusammenfassung 
Schlaganfall ist einer der 5 häufigsten Todesursachen in entwickelten Industrienationen. Jedes Jahr 
sterben weltweit schätzungsweise 6 Millionen Menschen an den Folgen eines Hirninfarktes. 
Zusätzlich ist Schlaganfall die häufigste Ursache für eine im höheren Alter erworbene Behinderung. 
Von allen Schlaganfällen sind etwa 85% ischämisch und nur etwa 15% intrazerebrale Blutungen. Die 
Hauptgründe für den ersten ischämischen Schlaganfall eines Patienten sind unter anderem Verschlüsse 
distaler Hirngefäße aufgrund von Gefäßstenosen (Makroangiopathie), Herzembolien oder 
Mikroangiopathien. Neben der akuten Lebensgefahr durch Schlaganfall spielen auch die hohen 
Rezidivraten nach einem ersten Schlaganfall eine wichtige Rolle. Das Risiko auf einen erneuten 
Schlaganfall ist bis zu 30 % höher in Schlaganfallpatienten, verglichen mit gleichaltrigen Patienten 
ohne Schlaganfall. Besonders hohe Rezidivraten korrelierten in mehreren Studien explizit mit 
Makroangiopathie. 
Nach Schlaganfall ist  neben komplexen neuroimmunologischen Alterationen auch eine  
multiphasische Immunreaktion des peripheren Immunsystems zu beobachten. Im Rahmen dieser 
Arbeit konnte gezeigt werden, dass die passive Sekretion von Alarminen—lösliche Botenstoffe nach 
neuralem Zelltod—als Schlüsselmediatoren dieser systemischen Immunalteration auftreten. Aus dem 
breiten Spektrum der Alarmine hervorzuheben ist hier das high mobility group box protein 1 
(HMGB1). Hierbei handelt es sich um ein Nicht-Histon-Protein im Zellkern, welches nach Sekretion 
in den extrazellulären Raum Zytokin-ähnliche Eigenschaften annimmt. HMGB1 interagiert mit 
sogenannten Pattern recognition receptors (PRR) und zeigt insbesondere für den Receptor of advanced 
glycation endproducts (RAGE) eine hohe Affinität. Generell sind PRRs in großer Zahl auf Zellen der 
angeborenen Immunabwehr exprimiert. Die HMGB1-RAGE Interaktionen können intrazelluläre 
Signalkaskaden aktivieren und sorgen so für eine Aktivierung der Immunzellen. Nur Stunden nach 
Auftreten des Infarkts kommt es bereits zu einer akuten Aktivierung des peripheren Immunsystems, 
welche in den darauffolgenden Tagen von einer subakuten Immunsuppression abgelöst wird. Aktuelle 
Forschungsarbeiten zeigen zudem ein Wiedererstarken des peripheren Immunsystems in Form einer 
chronischen Entzündungsreaktion, dies konnte bereits zuvor anhand von erhöhten Serumwerten für 
Entzündungsmarker (HMGB1, TNF-α, IL-6) gezeigt werden. 
Ziel der vorliegenden Arbeit war es herauszufinden, (1) wie Alarmine die systemischen 
Immunreaktionen nach Schlaganfall modulieren und (2) welche Signalkaskaden in Immunzellen 
hierbei eine Rolle spielen. Zudem wollten wir herausfinden, (3) ob der chronische Entzündungsstatus 
nach Schlaganfall Auswirkungen auf die Progression von Atherosklerose hat. 
Wir konnten im experimentellen Mausmodell zeigen, dass bei großen Infarkten bereits 30 Minuten 
nach Schlaganfall hohe Konzentrationen von HMGB1 im Serum zu finden sind. Serumanalysen von 
Schlaganfallpatienten ergaben ebenfalls hohe HMGB1-Werte innerhalb von wenigen Stunden nach 
Schlaganfall. Massenspektrometrie von murinem Serum nach Schlaganfall zeigte, dass innerhalb eines 
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Tages hauptsächlich die hochaktive Disulfidform von HMGB1 zu finden war. Dies ging einher mit 
einer frühen Aktivierung der angeborenen und adaptiven Immunität (stark erhöhte IL-6 und TNF-α 
Werte). In der Maus konnte die Immunaktivierung durch Antikörper-vermittelte Neutralisation von  
HMGB1 merklich abgeschwächt werden.  
Der aktivierte Immunstatus zeigte sich auch im Verhalten der Mäuse. Tiere mit Schlaganfall waren 
deutlich inaktiver und zeigten im Vergleich zu scheinoperierten Tieren einen gestörten zirkadianen 
Rhythmus. Neutralisation pro-inflammatorischer Zytokine führte zu einer sichtlichen Verbesserung 
des zirkadianen Rhythmus und der allgemeinen Aktivität der Mäuse. Wurde der für HMGB1 
hochaffine Rezeptor RAGE in Mäusen genetisch ausgeschaltet, so konnte man ebenfalls eine 
Verbesserung der Aktivität feststellen. 
Nach der akuten Aktivierung konnte in der subakuten Phase eine Expansion angeborener Immunzellen 
beobachtet werden. Dies ging einher mit einer Reduzierung der adaptiven Immunität, vor allem in der 
Milz. Die Anzahl der T Zellen in der Milz nach Schlaganfall verminderte sich um über die Hälfte der 
ursprünglichen Zellzahl. Auch hier zeigte eine Inhibition von HMGB1 bzw. ein Knockout von RAGE 
und anderen PRRs eine deutliche Verbesserung des Immunstatus.  
Zusammenfassend lässt sich sagen, dass unmittelbar nach Schlaganfall stark erhöhte HMGB1 
Konzentrationen im Blut von Mäusen und Patienten zu finden sind. Dies führt über die Aktivierung 
von PRRs, vor allem RAGE, zu einer rapiden Überaktivierung des peripheren Immunsystems. Die 
hohen Zytokinkonzentrationen äußern sich im Verhalten der Tiere, was bis zu Störungen des 
zirkadianen Rhythmus führt. In der anschließenden, subakuten Phase nach Schlaganfall führt eine 
Erschöpfung des Immunsystems zu einem massiven Lymphozyten-Verlust.  
 
Nach Charakterisierung der akuten und subakuten Phase nach Schlaganfall war die chronische Phase 
der schlaganfallinduzierten Immunantwort zentraler Gegenstand weiterer Nachforschungen. Wir 
stellten die Hypothese auf, dass die chronische Entzündung nach Schlaganfall die Pathophysiologie 
entzündlicher Komorbiditäten, wie zum Beispiel Atherosklerose (eine der häufigsten Komorbiditäten 
in älteren Patienten und Hauptursache für zerebrovaskuläre Vorfälle) beeinflusst.  Hierzu verwendeten 
wir ein etabliertes Mausmodell für Atherosklerose (ApoE–/–). Mithilfe einer kalorienreichen Diät 
(„Western Style Diet“) induzierten wir fortgeschrittene atherosklerotische Plaques. Einen Monat nach 
Induktion eines experimentellen Schlaganfalls fanden wir einen Anstieg der Plaquelast in Aorten und 
den Aortenklappen in den ApoE–/– Mäusen. Damit einhergehend war die myeloide Zellzahl in Aorten 
stark erhöht. Histologische Färbungen zeigten ausgedünnte fibröse Kappen um die Plaques und wir 
fanden Anzeichen für Rupturen einzelner Plaques. Als Grund für die erhöhte Zellzahl im Plaque 
konnten wir eine de novo Infiltration von Monozyten feststellen. In diesem Prozess spielt zum einen 
der CC-Chemokin Ligand 2 (CCL2) und dessen Rezeptor (CCR2) eine essentielle Rolle. Des Weiteren 
führt die Aktivierung des vaskulären Endotheliums durch Plasmamediatoren nach Schlaganfall zu der 
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Neueinwanderung von Immunzellen. Mithilfe von in vivo Magnetresonanztomografie konnten wir 
beobachten, dass nach Schlaganfall mehr VCAM1 vom aortalen Endothel exprimiert wird. Außerdem 
konnten wir zeigen, dass insbesondere HMGB1 in Interaktion mit RAGE eine wesentliche Rolle in der 
Immunaktivierung spielt. Zusätzlich detektierten wir erhöhte HMGB1 Konzentration einen Monat 
nach Schlaganfall in Mäusen. Sowohl in Patientenblut als auch in der Maus fanden wir bis zu 3 
Monaten nach Schlaganfall eine erhöhte Monozytenaktivität. Inhibition mithilfe eines Antikörpers 
gegen HMGB1 und systemischer knock down von RAGE mittels siRNA zeigten jeweils 
Abschwächung der Atheroprogression. 
Neben der Alarminsekretion ins Blut führt Schlaganfall ebenfalls zu einer sympathischen Innervation 
was zur Aktivierung des Knochenmarks führt. Bereits 24 Stunden nach Schlaganfall stellten wir 
vermehrte Migration von myeloiden Immunzellen aus dem Knochenmark in die Milz fest. Diesen 
Prozess konnten wir durch Injektion fluoreszierender Nanokristalle in das Knochenmark nach 
Schlaganfall darstellen und mithilfe von Beta Blockern inhibieren. 
Eine kombinierte Hemmung der sympathischen Innervation und der Alarmine mithilfe eines Beta-
Blockers und der löslichen Form von RAGE als Alarminrezeptor führte zu einer starken Reduktion der 
myeloiden Zellzahlen in der Aorta und verminderter Aktivierung der Monozyten. Zusätzlich konnte 
eine verminderte Plaquelast in den Aortenklappen festgestellt werden. 
Somit konnten wir in dieser Studie zeigen, dass Alarmine unmittelbar nach Schlaganfall das periphere 
Immunsystem aktivieren. Es kommt zu einer multiphasischen Kaskade aus akuter Immunaktivierung, 
subakuter Immunsuppression und erneuter chronischer Aktivierung des peripheren Immunsystems 
(Figure 5). Die chronische Entzündungsphase wirkt sich negativ auf die Komorbidität Atherosklerose 
aus. Indikator dafür war eine erhöhte Plaquelast und eine gesteigerte Plaquevulnerabilität. Wir konnten 
zeigen, dass ein Synergismus aus sympathetischer Aktivierung und Alarminsekretion die 
Atheroprogression vorantreibt. Wir konnten anhand der Ergebnisse dieser Studie Teile der beteiligten 
Mechanismen der Atheroskleroseprogression nach Schlaganfall erstmals aufzeigen und als neuartige 
therapeutische Ziele testen. Trotz der neuen Erkenntnisse werden aber weitere Studien nötig sein, um 
die genauen Prozesse der post-ischämischen Immunantwort, Atheroprogression und rezidivierender 
Schlaganfälle zu verstehen. 
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4 RESEARCH ARTICLES 
4.1  DAMP signaling is a key pathway inducing immune modulation after 
brain injury. 
Acute brain ischemia leads to complex neuronal immune cascades. Also in the periphery sterile brain 
injury induces profound alterations of the immune compartment. An early systemic immune activation 
within hours after stroke is followed by the opposing phenomena of subsequent immunosuppression. 
Animal models for experimental brain ischemia as a paradigm of acute brain lesions and additionally a 
large cohort of stroke patients were analyzed.  
Our results indicate that the cytokine-inducing, fully reduced isoform of high mobility group box 
protein 1 (HMGB1) is released from the ischemic brain in the hyperacute phase of stroke in mice and 
patients. Cytokine secretion of activated immune cells in the periphery in response to the brain injury 
induces a severe sickness behavior, which affected even the circadian rhythm of the rodent. This could 
be abrogated by inhibition of the HMGB1-RAGE pathway or direct cytokine neutralization. 
Subsequently, HMGB1-release induced monocyte mobilization and splenic proliferation of bone 
marrow-derived innate immune cells, inhibiting the peripheral adaptive immune response. Finally, 
HMGB1-RAGE interaction resulted in an exhaustive phenotype of monocytes and lymphopenia, a 
hallmark of subacute immunosuppression after large stroke.  
 
This study introduces the HMGB1-RAGE signaling pathway as one of the key mechanisms explaining 
the complexity of post-ischemic brain-periphery immune interactions. 
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Acute brain lesions induce profound alterations of the peripheral immune response comprising the opposing phenomena of early
immune activation and subsequent immunosuppression. The mechanisms underlying this brain-immune signaling are largely un-
known. We used animal models for experimental brain ischemia as a paradigm of acute brain lesions and additionally investigated a large
cohort of stroke patients. We analyzed release of HMGB1 isoforms by mass spectrometry and investigated its inflammatory potency and
signaling pathways by immunological in vivo and in vitro techniques. Features of the complex behavioral sickness behavior syndrome
were characterized by homecage behavior analysis. HMGB1 downstream signaling, particularly with RAGE, was studied in various
transgenic animal models and by pharmacological blockade. Our results indicate that the cytokine-inducing, fully reduced isoform of
HMGB1 was released from the ischemic brain in the hyperacute phase of stroke in mice and patients. Cytokines secreted in the periphery
in response to brain injury induced sickness behavior, which could be abrogated by inhibition of the HMGB1-RAGE pathway or direct
cytokine neutralization. Subsequently, HMGB1-release induced bone marrow egress and splenic proliferation of bone marrow-derived
suppressor cells, inhibiting the adaptive immune responses in vivo and vitro. Furthermore, HMGB1-RAGE signaling resulted in func-
tional exhaustion of mature monocytes and lymphopenia, the hallmarks of immune suppression after extensive ischemia. This study
introduces the HMGB1-RAGE-mediated pathway as a key mechanism explaining the complex postischemic brain-immune interactions.
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Introduction
Acute brain injuries, including stroke, induce profound altera-
tions of the peripheral immune system (Chamorro et al., 2012),
which contribute substantially to morbidity and mortality of pa-
tients. The best described component of these systemic immune
alterations is an acquired immune deficiency in the subacute
phase after ischemic stroke, which predisposes patients to infec-
tions (Meisel et al., 2005). The main features of this syndrome are
an inactivation of circulating monocytes and lymphopenia (Liesz
et al., 2009; Urra et al., 2009b). On the other hand, activation of
the peripheral immune system preceding the immunosuppres-
sive syndrome has also been consistently described (Offner et al.,
2006a). This sterile inflammatory response includes the massive
release of proinflammatory cytokines from systemic innate im-
mune cells within hours after the brain lesion (An et al., 2014).
Yet, the pathophysiological impact of this early immune activa-
tion as well as its mediators are unknown.
In view of the extensive impact of the perturbed peripheral
immune system on the damaged brain as well as on systemic
infectious complications, the identification of the signaling path-
ways underlying systemic immune modulation is of great trans-
lational relevance. Previous reports have suggested a role of the
autonomic nervous system in mediating subacute immunosup-
pression after acute brain injuries because elevated catechol-
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amine levels were observed in some of the previous experimental
stroke studies. Blocking of adrenoreceptors reversed aspects of
poststroke immunodepression, including susceptibility to bacte-
rial infections in experimental stroke (Prass et al., 2003; Meisel
et al., 2005). However, recent clinical (Liesz et al., 2013a) as
well experimental (Mracsko et al., 2014) studies have yielded
mixed results regarding the implications of catecholamines in
immunodepression.
Therefore, we focused in this study on soluble mediators re-
leased from the necrotic brain tissue as an alternative pathway in
poststroke brain-immune interaction. Previous studies suggested
a strong correlation between the volume of damaged brain tissue
and the extent of systemic immune alterations, regardless of in-
farct location (Gendron et al., 2002; Hug et al., 2009). Accord-
ingly, we speculated that soluble mediators would be released
from dying neurons in proportion to the extent of necrotic tissue.
As a prototypic alarmin, high mobility group box 1 (HMGB1) is a
nuclear protein, which is released from necrotic cells with high
inflammatory potency (Lotze and Tracey, 2005). As such,
HMGB1 can act itself as a cytokine or amplify the binding of
cytokines and nucleosomes to Toll-like receptors (TLRs) (Bian-
chi, 2009). The receptor of advanced glycation end-products
(RAGE) has been identified as a key receptor (in addition toTLR2
and TLR4) for HMGB1, mediating activation pathways to a va-
riety of cell types in an organ-specific manner (Lotze and Tracey,
2005).
Our study introduces the signaling of brain-released alarmins,
such as HMGB1, through RAGE as an important link between
acute brain injury and systemic immune alterations. We demon-
strate a biphasic scenario where this signaling cascade initially
activates peripheral monocytes and dendritic cells, resulting in a
massive release of proinflammatory cytokines. Subsequently, ini-
tial (over)activation of the peripheral immune system results in
exhaustion of monocytes and recruitment of immature mono-
cytes. Suppressive signaling by the altered monocyte population
leads to apoptosis of lymphocytes, the hallmark of poststroke
immunosuppression.
Materials and Methods
Animals. The study was conducted in accordance with national guide-
lines for the use of experimental animals, and the protocols were ap-
proved by the governmental committee (Regierungspraesidium
Karlsruhe, Germany). Animal experiments were designed, performed,
and data reported according to the ARRIVE guidelines (Kilkenny et al.,
2010). We used age-matched, male mice (C57BL/6J, 10 –12 weeks, 23–25
g body weight, Charles River Laboratories). RAGE / (Liliensiek et al.,
2004) and MyD88 / (Adachi et al., 1998) mice were bred in the core
animal facility of the University of Heidelberg under specified pathogen-
free conditions.
Patient recruitment and blood sampling. Blood samples used for anal-
ysis in this study were collected during a previous study (Liesz et al.,
2013a) conducted between October 2011 until November 2012. In brief,
inclusion criteria were study enrollment within 24 h after symptom on-
set. Exclusion criteria were recent clinical infection (fever, cough, antibi-
otic treatment, laboratory markers) within 14 d before admission, a
chronic immunological disorder, preexisting immunosuppression, can-
cer, and pregnancy. Blood samples from 104 patients obtained within
24 h after symptom onset were analyzed. Patient characteristics are de-
picted in Tables 1 and 2. Stroke patients received routine cranial imaging
by CT (Somatom Sensation 16) and/or 3T MRI (Trio and/or Verio; all
Siemens Medical Systems) to detect ischemic brain lesions. Volume was
calculated by integrating areas on each image multiplied by section di-
ameter using a Syngo Multimodality workplace with syngoMMWP-
software (version VE31A, Siemens). For the control group, patients were
included that presented at the Department of Ophthalmology for pre-
surgical screening for cataract operation. Patients were selected to be in
the same range for age and gender of patients with cerebrovascular dis-
orders. All procedures were performed after written informed consent
was obtained by the patient or a legal representative.
Animal experiments. Animals received intraperitoneal injection of 100
g monoclonal anti-HMGB1 antibodies (clone 2g7) (Qin et al., 2006) 30
min before ischemia induction or an isotype control antibody (BioX-
Cell); 100 g soluble RAGE (full-length recombinant human sRAGE)
was injected before middle cerebral artery occlusion (MCAO) induction
and 4 h after MCAO. The 2-adrenoreceptor inhibitor ICI 118,551
(Sigma) was administered intraperitoneally at 4 mg/kg body weight be-
fore MCAO and at 4, 8, and 12 h after MCAO (Mracsko et al., 2014).
Neutralization of circulating cytokines was achieved by intraperitoneal
injection of 200 g each of anti-IL-1beta, anti-TNF-, or anti-IL-6 anti-
bodies (all from eBioscience, functional grade purified) in a total volume
of 200 l PBS intraperitoneally. Control mice received 300 g of isotype
control antibody. Organ sampling (brain, spleen, thymus, bone marrow,
blood from retro-orbital sinus) for further analysis was performed in
anesthesia with ketamin/xylazine. Rectal temperature and body weight
were measured daily. Neurological deficits were assessed by a modified
“Bederson score” (Bederson et al., 1986): 0, no deficit; 1, forelimb flexion;
Table 1. Patient characteristics of stroke and control patients for HMGB1 blood
analysis
Controls Stroke patients p
Total patients per group 20 104
Age (years) 69.3  9.2 73.2  10.4 0.241
NIHSS on admission 0 11.7  6.4 —
Median stroke volume (ml) NA 29.4 —
Laterality (right/left) NA 53/51 —
Blood samples (n) obtained within 24 h
after symptom onset
NA 104 —
Blood samples (n) obtained within 72 h
after symptom onset
NA 153a —
Mean time: symptom onset to first blood
sampling (hours)
NA 10.7  5.2 —
Comorbidities
Hypercholesterolemia 6 (30%) 27 (26%) 0.998
Arterial hypertension 17 (85%) 72 (69%) 0.151
Diabetes 7 (35%) 30 (29%) 0.581
Premedication
-AR blocker 7 (35%) 39 (38%) 0.832
Oral anticoagulationb 4 (20%) 17 (16%) 0.689
Antithromboticsc 8 (27%) 17 (24%) 0.167
Sympathicoactive medicationd 3 (15%) 7 (7%) 0.069
aForty-nine patients were measured twice (at hospital admission and at day 3 after stroke onset).
bPhenprocoumon, rivaroxaban.
cAspirin, aspirin  dipyridamole, clopidogrel.
dClonidin, oxybutinin, inhalable 2-AR agonists, doxazosin, terazosin.
Table 2. Patient characteristics of stroke and control patients for MDSC FACS (Fig. 3D)
Patient
Age
(years) Hypertension Diabetes
Lesion
localization NIHSS
Lesion volume
(cm 3)
Control 1 67   NA NA NA
Control 2 91   NA NA NA
Control 3 86   NA NA NA
Control 4 84   NA NA NA
Control 5 31   NA NA NA
Control 6 64   NA NA NA
Stroke 1 69   MCA, R 18 143
Stroke 2 76   MCA, R 33 317
Stroke 3 87   MCA, R 24 214
Stroke 4 43   ACA  MCA, L 19 293
Stroke 5 64   MCA, L 22 184
Stroke 6 73   MCA, R 18 174
NA, Not applicable; ACA, anterior cerebral artery; R, right; L, left.
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2, decreased resistance to lateral push; 3, unidirectional circling; 4, lon-
gitudinal spinning; 5, no movement. Sensorimotor deficit was measured
using the Rotarod test as previously described (Jones and Roberts, 1968;
Liesz et al., 2013b). Briefly, mice were trained at first at constant 4 rpm,
then three times at acceleration from 4 to 40 rpm in 210 s. Baseline
assessment was performed as for training with acceleration and the mean
calculated from three runs with a 10 min break in between. Time was
stopped if the mouse fell off the beam or passively rotated twice on the
beam. Assessment 24 h after MCAO was performed similar to baseline
measurement.
Experimental stroke models
Coagulation model. We used this stroke model for experiments shown in
Figure 1A, B. Mice were anesthetized with 1.0%–2.0% halothane in O2/
Figure 1. Inhibition of the HMGB1 pathway after stroke improves mortality. A, Representative cresyl-violet-stained brain sections (left) after permanent distal MCA occlusion (C-MCAO), 30 min
or 90 min transient proximal filament-MCAO (F30-MCAO and F90-MCAO), and analysis of mean infarct volumes in the respective MCAO model (3 d after MCAO, n  12–15 per model, C57BL/6J WT
mice). B, Serum HMGB1 concentration was measured by ELISA in unoperated naive animals, in the three stroke models, and in respective sham-operated animals (C-sham and F-sham, respectively)
at the indicated time points after MCAO (n  6 per group). *p  0.05, between naive and the indicated group. Bars represent p  0.05 between marked groups within one time point. Data are
representative for 3 individual experiments per time point. C, Increase of serum HMGB1 in the 90 min filament-occlusion model was verified by Western blot analysis at 2 h after MCAO compared with
the sham-operated control mice (n  4 per group). D, Dot plot analysis of HMGB1 serum concentrations of ischemic stroke patients up to 72 h after stroke onset (n  153). E, Serum HMGB1 was
measured in matched control patients without stroke (n  20) and in stroke patients. For analysis of stroke patients (n  104), only blood samples of individual patients (no repetitive
measurements) up to 24 h after symptom onset were included and patient groups dichotomized into small/moderate (30 ml) and severe (30 ml) lesion volumes. F, Stroke lesion volume was
analyzed 3 d after 90 min filament-occlusion MCAO (F-90 min) in control animals (C57BL/6J) and RAGE / animals receiving anti-HMGB1 or control (isotype IgG) treatment. Infarct volumes did not
significantly differ among groups (n  18 –34 per group, 4 individual experiments, p  0.21). G, The Bederson score reflecting poststroke motor deficits was not affected by anti-HMGB1 treatment
or RAGE deficiency. H, Kaplan–Meier curves of poststroke survival within the first week after F-90 min MCAO in control, anti-HMGB1 treated, and RAGE / mice. Overall p value  0.02: Mantel-Cox
test; n  32(control), 17(RAGE /), 22(anti-HMGB1). p value (RAGE / vs control)  0.008. I, Body weight (left) and rectal body temperature (right) were measured before surgery and on
poststroke days 1–3 (n  15–18 per group). *p  0.05, control versus RAGE /. #p  0.05, control versus anti-HMGB1. F–I, Data are representative of 4 individual experiments.
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N2O. After making a 1 cm skin incision between the left eye and ear, we
drilled a burr hole through the temporal skull. We removed the dura
mater and occluded the MCA permanently using a bipolar electrocoag-
ulation forceps (ERBOTOM, Erbe). During the operation, body temper-
ature was kept at 37°C using a feedback controlled heating pad. We
sutured the skin lesion and placed the mouse in a cage under an infrared
heating lamp until recovery from anesthesia. Sham treatment was given
according to the same surgical protocol as for MCAO but without coag-
ulation of the MCA. The overall mortality in the coagulation model was
5% for the 3 d observation period.
Filament model. We used this model for all remaining experiments.
Mice were anesthetized with 1.0%–2.0% halothane in O2/N2O-enriched
air. We placed the laser Doppler probe over the cortical area supplied by
the MCA. Baseline CBF was measured as relative perfusion units and
defined as 100% flow. After neck dissection, we made an incision into the
left external carotid artery between two ligations and advanced a silicon-
covered 8-0 nylon monofilament through the internal carotid artery to
occlude the MCA. MCA occlusion was documented as a decrease in
relative perfusion values by laser Doppler to 20% of original flow, a less
pronounced decrease in CBF was used as an exclusion criterion. We fixed
the filament in this position by ligation, closed the neck, removed the
Doppler probe, and placed the mouse in its cage. Then, 30 min (only for
experiments in Fig. 1 A, B) or 90 min, respectively, after filament inser-
tion, the mouse was anesthetized again and the filament removed. After
we closed the surgical wound, the mice were transferred to their cages
with free access to water and food. During the operations body temper-
ature was kept at 37°C with a feedback-controlled heating pad. We main-
tained normal body temperature of the mice between operations and
until recovery after the procedure by an infrared heating lamp. Sham
operation was performed in exactly the same manner as described above,
including repeated anesthesia 30 or 90 min after sham surgery, except
that the filament was only introduced briefly into the external carotid
artery. The overall mortality in the 30 min occlusion model was 5% for
the 3 d observation period; mortality for the 90 min occlusion model is
reported in Figure 1H.
Assessment of infarct volume. We anesthetized the mice and perfused
them transcardially with 20 ml normal saline. We removed the brains
from the skull and froze them immediately in isopentane (20°C). We
cut 20-m-thick coronal cryosections every 400 m, stained the sections
using a standard cresyl-violet staining protocol, scanned them at 600 dpi,
and analyzed the infarct area on each section (ImageJ). The Swanson
method was applied to indirectly measure the infarct area and to
correct for cortical swelling (Swanson et al., 1990). The total infarct
volume was determined by integrating measured areas and distances
between sections.
Analysis of HMGB1 by electrospray ionization liquid chromatography
mass spectrometry. All chemicals and solvents were of the highest avail-
able grade (Sigma). Samples were precleared with 50 l protein
G-Sepharose beads for 1 h at 4°C. Supernatant HMGB1 was immuno-
precipitated with 5 g rabbit anti-HMGB1 (Abcam; ab18256) for 16 h at
4°C as previously described (Antoine et al., 2009). Free thiol groups
within HMGB1 were alkylated for 90 min with 10 mM iodoacetamide at
4°C. Cysteine residues in disulfide bonds were then reduced with 30 mM
DTT at 4°C for 1 h followed by alkylation of newly exposed thiol groups
with 90 mM NEM at 4°C for 10 min. Samples were subjected to trypsin
(Promega) or GluC (New England Biolabs) digestion according to man-
ufacturer’s instructions and desalted using ZipTip C18 pipette tips (Mil-
lipore). Characterization of whole protein molecular weights, acetylated
lysine residues, or redox modifications on cysteine residues within
HMGB1 were determined as described previously by whole protein elec-
trospray ionization or tandem mass spectrometry (Antoine et al., 2012;
Nyström et al., 2013) using either an AB Sciex QTRAP 5500 or an AB
Sciex TripleTOF 5600 (Sciex Inc.). Peptide analysis was determined using
an AB Sciex QTRAP 5500 equipped with a NanoSpray II source by in-line
liquid chromatography using a U3000 HPLC System (Dionex), con-
nected to a 180 m  20 mm nanoAcquity UPLC C18 trap column and
a 75 m  15 cm nanoAcquity UPLC BEH130 C18 column via reducing
unions. A gradient from 0.05% TFA (v/v) to 50% ACN/0.08% TFA (v/v)
in 40 min was applied at a flow rate of 200 nl/min. The ionspray potential
was set to 2200 –3500 V, the nebulizer gas to 19, and the interface heater
to 150°C.
ELISA. Human and mouse serum and cell culture supernatants were
collected and immediately frozen at 80°C until analysis. Commercial
ELISA kits were used for the quantitative analysis of HMGB1 (IBL) and
cytokine expression of IL-1, TNF-, IL-6, and IL-12p40 (all R&D
Systems).
Homecage behavior analysis. Mice were held individually in 37  16 
13 cm transparent plastic cages as homecages. Mice were recorded for
17–24 h for each day/night/d cycle before MCAO and at day 1 and/or day
3 after MCAO using CCD cameras and an infrared illumination system
during the dark cycle. The camera angle was set up for recording of the
long side of cages to observe horizontal as well as vertical activities, such
as rearing and hanging. Ethovision (EthovisionXT, version 4.1, by Nol-
dus Information Technologies) video tracking software was used to dig-
itize the trials at a rate of 12.5 frames/s. Total distance moved, rearing
time, and rearing frequency were determined using animal center point
analysis according to areas indicated in Figure 2F.
Bacterial culture. For bacterial blood cultures, 30 l blood was drawn
from each mouse and diluted in 270 l sterile PBS. For bacterial lung
cultures, both lung lobes were homogenized in PBS in a total volume of
300 l; 50 l of each blood sample or 100 l of each lung homogenate
was plated on Columbia agar with 5% sheep blood (BD Biosciences).
Plates were incubated at 37°C in the presence of 5% CO2 and colony
forming units were evaluated after 24 h.
Determination of bacterial DNA in lung homogenates by quantitative
PCR. Bacterial load in lung homogenates was determined applying a
quantitative real-time PCR that amplifies 16S ribosomal DNA. Both lung
lobes were homogenized, and DNA was extracted using the QIAmpDNA
Mini kit (QIAGEN) according to the manufacturer’s instructions with an
eluate volume of 100 l. Samples were amplified with primers targeting
conserved regions within the 16S rRNA gene (forward, 5	-TGG AGC
ATG TGG TTT AAT TCG A-3	; reverse, 5	-TGC GGG ACT TAA CCC
AAC A-3	). A defined plasmid standard (16S rRNA amplicon from Esch-
erichia coli, cloned in pCR2.1, Invitrogen; plasmids quantified by spec-
trophotometry) was used as positive control for qPCR. Samples were
assayed in triplicate in a 25 l reaction mixture containing 2 l of tem-
plate DNA, 12.5 l of 2 Fast SYBR Green Master Mix (Applied Biosys-
tems) and 12.5 pmol of forward primer and reverse primer (MWG).
Cycling conditions were as follows: 95°C for 10 min, followed by 40
cycles at 95°C for 15 s and 60°C for 1 min each. For quantification,
background levels of the nontemplate control were subtracted from
the specific samples.
Western blotting. Proteins were isolated for HMGB1 and ARG1 West-
ern blotting from samples using ice-cold RIPA buffer as previously re-
ported (Liesz et al., 2013b). Lysates were electrophoresed, transferred to
nitrocellulose membranes, and blocked with skim milk. Blocked mem-
branes were probed with rabbit anti-HMGB1 (1:1000) or incubated with
sheep anti-ARG1 (1:500; R&D Systems) in TBS-T plus 5% milk over-
night at 4°C Peroxidase-conjugated goat anti-rabbit and donkey anti-
sheep secondary antibodies were used, respectively, and blots developed
by standard chemiluminescence protocols.
Stress mediator analysis. Serum cortisol and metanephrine/normeta-
nephrine concentrations were measured in the central laboratory of the
University Hospital Heidelberg by the same procedures used and vali-
dated for routine diagnostic analysis. Cortisol concentrations were mea-
sured by chemiluminescence immunoassays, and serum metanephrine/
normetanephrine were detected by ELISA.
Magnetic cell sorting. MACS sorting using magnetic beads was used for
isolation of CD11b-, CD11c-, and CD3-positive cells for in vitro studies.
Single-cell suspensions were prepared from spleens of the respective na-
ive donor animals or after experimental brain ischemia as indicated in
the manuscript. Single-cell suspensions were then processed for further
purification of the subpopulation according to the manufacturer’s pro-
tocol using commercial MACS kits (Miltenyi Biotec) for the purification
of the indicated population (total T cells, monocytes, dendritic cells,
myeloid-derived suppressor cells).
Real-time PCR. RNA was isolated from spleens or isolated cells using
the RNeasy kit (QIAGEN). Reverse transcription was performed with the
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Figure 2. HMGB1 is released from necrotic brain tissue and matures to its cytokine-inducing form. A, Mass spectrometric characterization of the critical HMGB1 isoform with cytokine-inducing
properties as categorized by the C23–C45 disulfide (NEM adduct) redox form. B, Representative spectrum of the tandem mass spectrometric characterization of a peptide (amino acids 180 –188)
covering the lysine (K) residues within nuclear localization sequence (NLS) 2 of HMGB1, depicting the hyperacetylated state of HMGB1-NLS2. Acetyl modifications are represented as (ac) on specific
lysine residues (K181, K182, K183, and K184). C, D, Tabular overview of the detected isoforms of post-translationally modified HMGB1 in ipsilateral brain hemispheres and serum samples at 2 h (C)
and 24 h (D) after F-90 min MCAO. Gray shading represents the presence of redox isoforms at cysteine residues and of the acetylation state at lysine residues within both nuclear localization signals
(NLS) of HMGB1. C23–C45 disulfide isoforms mediate the cytokine-inducing HMGB1 activity. Hypoacetylation of the NLS regions indicates the nuclear localization and origin of HMGB1. Hyperacety-
lation of HMGB1’s NLS regions is involved in cytoplasmatic shuttling of HMGB1.
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High Capacity complementary DNA Archive Kit and real-time PCR with
SYBR-Green assays on an ABI7500 real-time PCR system (Applied Bio-
systems). Primers were purchased as ready-to-use primer sets for each
gene (Super Array). All assays were run in duplicate. Expression of each
gene was quantified according to the relative standard curve method
relative to the expression of the housekeeping gene encoding for -actin.
In vitro assays
T-cell stimulation assay. For intracellular cytokine staining of isolated T
cells, we plated single-cell suspensions of 300,000 mononuclear cells
on 96-well plates (RPMI-1640,  10% FCS,  glutamine, HEPES, 
penicillin/streptomycin,  mercaptoethanol). Each sample was pro-
cessed in triplicate. We primed the cells for 48 h with plate-bound anti-
mouse CD3e (clone 145-2C11, BD Biosciences) and 2 g/ml soluble
anti-mouse CD28 (clone 37, clone 51, BD Biosciences), followed by re-
stimulation with 500 ng calcimycin (Sigma-Aldrich), 5 ng/ml PMA
(Sigma-Aldrich), and protein transport inhibitor (BD GolgiPlug, BD
Biosciences) for 5 h.
Dendritic cell stimulation assay. CD11c  splenic dendritic cells were
isolated by MACS following the manufacturer’s protocol (Miltenyi
Biotec). CD11c  cells were cultured at a concentration of 100,000 cells/
well for 24 h. Fully phosphorothioate modified CpG-ODN 1668 (TIB
Molbiol) was used at a concentration of 100 nM by adding the stimulus
directly into the culture medium.
Marrow-derived suppressor cell (MDSC) suppression assay. CD11b Ly-
6Chigh
 cells were isolated by MACS and cocultered with CD3  T cells
(MACS-isolated) at the indicated ratio with a total cell count of 200,000
cells per well of a 96-well round-bottom plate. T cells were labeled with
CFSE (CFSE cell proliferation kit, Invitrogen), and their proliferation
was stimulated by plate-bound anti-CD3 (10 g/ml) and addition of
concavalin A at 2 g/ml for a culture time of 42 h. Suppression of T-cell
proliferation was assessed by measuring the CFSE dilutions and analyzed
using Flowjo 4.2 software (TreeStar).
HMGB1 stimulation assay. For assessment of the cytokine-inducing
activity of HMGB1, mixed splenocyte cultures (Fig. 2D) or cocultures of
T cells with antigen-presenting cells (APCs) (Fig. 2E) were used.
Erythrocyte-depleted primary cell suspensions of spleens from naive an-
imals were used for mixed splenocyte cultures. For cocultures, T cells
were isolated by MACS (T cell isolation kit I, Miltenyi) and APCs were
isolated using the same kit. APCs were either irradiated or received sham
treatment (placement in chamber with no irradiation). Cells were cul-
tured in RPMI-1640 medium, “Cytokine HMGB1”(C23-C45 disulfide
bond, purchased from HMGBiotech) was added to the culture medium
at the indicated concentrations.
Flow cytometry. We collected organs (spleen, blood, mesenteric lymph
nodes, and bone marrow) after transcardial perfusion with saline at var-
ious time points after MCAO for flow cytometric analysis. We stained
single-cell suspensions for anti-mouse CD3 (clone 17A2), CD4 (clone
RM 4 –5), CD8 (clone 53– 6.7), B220 (clone RA3– 6B2), NK1.1 (clone
PK136), Ly-6C (clone HK1.4), Ly-6G (Gr-1; clone RB6 – 8C5), CD80
(clone 16 –10A1), CD86 (clone GL1), CD25 (clone PC61), CD69 (clone
H1.2F3), CD11b (clone M1/70), MHC-II (M5/114.15.2), and CD11c
(clone N418). Expression of IFN- (clone XMG1.2) and IL-4 (clone
11B11) was intracellularly detected after stimulation of T cells by the
above published stimulation protocol.
Blood samples from stroke patients for FACS analysis were collected in
EDTA tubes and immediately processed. Mononuclear cells were iso-
lated by Ficoll gradient centrifugation and single-cell suspensions stained
for anti-human CD11b (clone ICRF44), CD33 (clone P67.6), and
HLA-DR (clone L243). We performed flow cytometry on a Becton Dick-
inson FACS Calibur and analyzed the data by CellQuest Pro software.
Statistical analysis. Sample size of the experiments was determined by a
priori calculation presuming Type I error of 0.05, power of 0.8, and
specific variance based on according preexperiments using g* power sta-
tistical software. All values in bar graphs are expressed as mean  SD. We
analyzed infarct volumes and functional outcome tests by two-tailed
Student’s t test after validating the normal distribution of these datasets
(Kolmogorov–Smirnov test) or for 2 groups by ANOVA with Tukey
post hoc analysis. For the remaining data without normal distribution, we
used two-tailed Wilcoxon rank-sum test for two groups or the Kruskal–
Wallis test with Dunn’s multiple comparison post hoc analysis test for
more than two groups, using GraphPad Prism 5 software. p  0.05 was
considered statistically significant.
Results
HMGB1 is released from necrotic brain lesions
We analyzed HMGB1 serum concentrations by ELISA in differ-
ent experimental stroke models varying by location and volume
of the resulting infarct (Fig. 1A) and detected a significant in-
crease only after large infarcts at early time points after stroke
(Fig. 1B). This was verified by HMGB1 Western blotting at 2 h
after stroke onset (Fig. 1C). We also found massively increased
HMGB1 serum concentrations in stroke patients within the first
hours after symptom onset (Fig. 1D). To verify HMGB1 release in
human stroke, we further evaluated HMGB1 concentrations in
blood samples from 104 patients (patient characteristics summa-
rized in Table 1) within 24 h after symptom onset of small or large
lesions (dichotomized by the median infarct volume, in this co-
hort 30 ml) and compared it with control patients (Fig. 1E).
Because human and murine results showed a consistent pattern
of early HMGB1 release into the circulation after extensive isch-
emic brain lesions, further experimental studies were performed
exclusively in the 90 min transient MCAO model.
We analyzed the impact of blocking HMGB1 by neutralizing
antibodies or by elimination of its receptor RAGE in knock-out
mice on stroke outcome. Infarct volumes (Fig. 1F) and basic
sensory-motor deficits measured by the Bederson score (Fig. 1G)
did not differ significantly among anti-HMGB1 treated animals,
RAGE/ mice, and controls in our experiments. Intriguingly,
despite the lack of effect on infarct size and neurological deficit,
7 d mortality was substantially reduced in RAGE/ mice (p 
0.008, n  22) and tended also to be lower in anti-HMGB1-
treated mice (p  0.07, n  17) (Fig. 1H). Both HMGB1 neu-
tralization and RAGE deficiency also attenuated loss of body
weight and hypothermia after stroke (Fig. 1I). This dissociation
between similar lesion size and differing mortality might indicate
that HMGB1-RAGE blockade modified important systemic con-
sequences of brain infarction rather than resulting in immediate
structural neuroprotection.
HMGB1 matures in the circulation to its cytokine-
inducing isoform
Because the biological activity of HMGB1 is critically dependent
on the redox state of cysteine residues at C23, C45, and C106
(Yang et al., 2013), we analyzed post-translational HMGB1 mod-
ifications by tandem mass spectrometry (Fig. 2A,B). At 2 h after
ischemia, the fully reduced isoforms with no cytokine-inducing
but chemoattractant activity predominated in brain and serum
samples as the disulphide form was not detected in any of the
investigated brains and only in two often serum samples. More-
over, the exclusively hypoacetylated state confirmed the passive
release of HMGB1 from necrotic cells (Fig. 2C, summary). In
contrast, the cytokine-inducing C34-C45 disulphide HMGB1
isoform (Yang et al., 2010) was found as the prevalent isoform in
serum samples at 24 h but could still not be detected in brain
samples of the corresponding animals (Fig. 2D). These results
indicate HMGB1 maturation in the blood circulation toward its
cytokine-stimulating isoform after initial (passive) release from
the necrotic brain tissue.
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The early phase after brain injury is characterized by massive
systemic cytokine secretion mediating sickness behavior
To determine the contribution of HMGB1 signaling on sterile
systemic inflammation, cytokine concentrations were deter-
mined within the acute phase after brain ischemia. Expression
levels of the proinflammatory cytokines IL-1, TNF-, and IL-6
were markedly increased in the acute phase after stroke onset
(Fig. 3A). Antibody-mediated neutralization of HMGB1 signifi-
cantly attenuated splenic expression and serum concentrations of
these proinflammatory cytokines (Fig. 3A,B). Supporting the
immune-stimulatory role of HMGB1, in vitro stimulation of
splenocyte cultures with the cytokine-stimulating isoform of
HMGB1 resulted in increased expression of T cell- (IFN-) and
monocyte- (IL-12) derived cytokine secretion (Fig. 3C). More-
over, we detected a dose–response relation for HMGB1 concen-
tration and IFN- secretion by isolated T cells, which depended
on the presence of viable APCs (Fig. 3D).
Weight loss and hypothermia, as shown in Figure 1I, are con-
sidered as basal markers of sickness in models of immune-
mediated diseases (Dantzer, 2006). We further investigated this
phenomenon in a homecage behavior analysis setup, which en-
abled the automated analysis of circadian rhythm and complex
mouse behavior (Jhuang et al., 2010; Spulber et al., 2012) (Fig.
4A). Although no behavioral difference was detected between
RAGE/ animals and WT controls at baseline before MCAO (data
not shown), we detected a disturbance in circadian rhythm at day 1
after stroke. This was more pronounced in WT compared with
RAGE/ animals with respect to arousal after the start of the day
cycle (6 A.M.) and disparity between overall night and day activity
(Fig. 4B). Furthermore, mobility and exploratory behavior (total
distance moved), targeted movements to reach the water bottle
(rearing time and frequency), and challenging physical activities
(hanging time) were significantly less affected during the early phase
after stroke induction in RAGE/ compared with WT mice (Fig. 4C).
To investigate the role of the peripheral cytokine release in the
acute phase after brain injury as the potential link between RAGE
deficiency and improved behavior, we antagonized IL-1,
TNF-, and IL-6 by neutralizing antibodies and analyzed key
features of sickness behavior as introduced above. Infarct volumetry
revealed similar infarct volumes in control- and anti-cytokine–
treated mice (Fig. 4D). Additionally, focal sensorimotor dysfunction
analyzed by the Rotarod test did not differ between the treatment
groups (Fig. 4E). This demonstrated that peripheral cytokine neu-
tralization had no immediate impact on the primary brain lesion. In
contrast, homecage behavior analysis revealed a similar treatment
effect of cytokine antagonization as previously seen in RAGE-
deficient mice. The cytokine neutralization improved the stroke-
induced disturbances in circadian rhythm with reduced variation
between light and dark periods (Fig. 4F). It also improved overall
motility as depicted by analysis of total distanced moved in the first
2 h of the light period (6 A.M. to 8 A.M.) (Fig. 4G).
RAGE signaling promotes MDSC expansion
Based on the finding that APC viability is critical for the impact of
HMGB1 on lymphocyte function (Fig. 3D), we further analyzed
the role of monocytes in this model. We found an expansion of a
specific immature monocyte subpopulation in the spleen, char-
acterized by the CD11bLy-6CMHC-IIlow expression pattern
after stroke (Fig. 5A), which was abrogated by anti-HMGB1
treatment (Fig. 5B). Further analysis of this population in spleen
and bone marrow revealed both increased splenic proliferation
(marker Ki-67) and a reduced proportion of this subpopulation
Figure 3. HMGB1 signaling induces early innate and adaptive immune activation. A, Cytokine mRNA expression was analyzed in spleens at the indicated time points after MCAO (n  7 per group
and time point). B, Expression levels of IL-1 and TNF- were verified on protein level in the serum of control mice (isotype IgG) and anti-HMGB1-treated mice without brain lesion (naive) and 24 h
after F-90 min MCAO by ELISA (n  6 per group). A, B, Data are representative of 2 individual experiments per time point. C, The cytokine-inducing function of HMGB1 was tested in vitro.
Interferon- (left) and IL-12 (right) concentration was analyzed in supernatants of mixed splenocyte cultures stimulated with disulphide-HMGB1 at the indicated concentration and compared with
unstimulated samples (control). Bars represent p  0.05 between indicated groups. Each data point represents one individual experiment. D, Naive CD3  T cells were cocultured with untreated
(vital) or irradiated APCs and stimulated with HMGB1 at the indicated concentration for 24 h. Interferon- concentrations were measured in the supernatant by ELISA (data representative of 5
individual experiments). Vital APCs are required for stimulation of IFN- production by T cells.
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in the bone marrow (Fig. 5B). These findings are compatible with
a combination of local splenic proliferation as well as bone mar-
row egress of immature monocytes. Moreover, stroke in WT
mice resulted in an increase in CD80 expression and a reduction
of MHC-II expression on monocytes (Fig. 5C). The stroke-
induced rise of immature splenic monocytes compared with
sham-operated mice was significantly reduced in RAGE/ ani-
mals 3 d after MCAO, supporting the role of HMGB1-RAGE
signaling on immature monocyte recruitment (Fig. 5D).
To assess functional capabilities of splenic monocytes after
stroke that were independent of the RAGE signaling pathway, we
performed stimulation assays with the TLR9-ligand CpG-ODN.
Figure 4. RAGE signaling mediates sickness-like behavior in the acute phase after stroke. A, Representative images of the unmodified tracking zones for continuous recording by the homecage
behavior system (top). Analysis fields (hanging and rearing zones) and tracking (red lines) of mice in their home cages, indicated for 1 h recording (bottom). B, Brain ischemia by F-90 min MCAO
induces a disturbed circadian rhythm with reduced activation response after a shift of night-day cycle at 6 A.M. Data are depicted for total distance moved per 1 h during the 12 h recording period
(6 h dark and light cycle, each) and indicate a different degree of disturbed circadian rhythm between RAGE / and WT mice at day 1 (d1) after MCAO. C, Results of the homecage behavior analyses
for overall mobility (moving distance: left) or motivation to challenging physical activity (rearing time: middle; hanging time: right) shown as cumulative data during the 2 h period from 6 A.M. to
8 A.M. at day 1 and day 3 after MCAO in WT control and RAGE / mice. Data were obtained in 3 individual experiments. D, Infarct volumetry 24 h after 90 min transient MCAO in mice receiving
neutralizing antibodies against IL-1, TNF-, and IL-6 (anti-cytokine) or isotype control IgG (control). E, Sensorimotor deficits were determined in the corresponding groups as in D and in a
sham-operated group 24 h after F-90 min MCAO and normalized to baseline values. n.s., Not significant. F, The disturbed circadian rhythm after MCAO compared with sham treatment is improved
in the anti-cytokine treated group as depicted by the approximation of the activity pattern to one of mice with sham surgery. G, Analysis of the total distance moved within the first 2 h of the light
period (6 A.M. to 8 A.M.). D–G, Data were obtained from 3 individual experiments; n(sham)  9, n(control)  9, n(anti-cytokine)  9.
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This revealed substantially reduced IL-12 and TNF- secretion
by monocytes 3 d after brain ischemia consistent with a reduced
responsiveness of splenic monocytes resulting from functional
exhaustion. In vivo anti-HMGB1 treatment partially attenuated
monocytic hyporesponsiveness to in vitro stimulation as
shown by increased IL-12 secretion in the anti-HMGB1-
treated group compared with control mice, although it had no
effect on TNF- production (Fig. 5E). Next, we analyzed the
frequency of immature monocytes, delineated by expression
of CD11bCD33HLA, in stroke patients with extensive brain
lesions (100 ml lesion volume) and matched control patients
without neurological disease (Fig. 5F; Table 2). We detected a
significant expansion of immature monocytes also after human
stroke (Fig. 5G). We further analyzed the functional properties of
the expanded CD11bLy-6C monocyte population to stimu-
late or inhibit T cells. Splenic CD11b monocytes isolated 3 d
after stroke used as APCs in coculture with CD3 T cells had a
suppressive effect on T-cell proliferation (Fig. 5H, I). Addition-
ally, arginase-1 (Arg1) expression, a marker of myeloid-derived
suppressor cells (Rodríguez and Ochoa, 2008; Gabrilovich and
Nagaraj, 2009), was massively increased in poststroke splenic
monocytes, which was prevented by in vivo pretreatment with
anti-HMGB1 (Fig. 5J).
Poststroke lymphocytopenia in the subacute phase is partially
mediated by HMGB1 signaling
We investigated the role of the HMGB1-RAGE pathway on the
previously documented decrease in immune cell cellularity in the
subacute phase after stroke (Prass et al., 2003; Offner et al., 2006b;
Liesz et al., 2009) (Fig. 6A–D). RAGE deficiency, but not anti-
HMGB1 treatment, reduced splenic lymphocyte apoptosis after
brain ischemia (Fig. 6A,B). Similarly, the stroke-induced reduc-
tion of circulating blood T cells was prevented in RAGE-deficient
mice (Fig. 6C). The postischemic effect on B-cell and granulocyte
counts, however, was not influenced by either anti-HMGB1
treatment or by RAGE- or MyD88 deficiency, respectively (data
not shown). Furthermore, we observed a relative increase of ac-
tivated T cells (activation markers CD25 and CD69) in RAGE/
mice compared with WT mice after stroke (Fig. 6D). Because of
the incomplete antagonization of the immunosuppressive phe-
notype by RAGE deficiency, we further investigated the impact of
TLR-mediated pathways in stroke-induced immune distur-
bances using MyD88/ mice. We detected a similar pattern for
T-cell counts in spleen and blood as for RAGE/ mice after
stroke with partial abrogation of lymphopenia in MyD88/
mice without further augmentation by anti-HMGB1 treatment
(Fig. 6E). In summary, these results indicate that the immuno-
suppressive and lymphotoxic effects of extensive brain ischemia
are mediated at least in part by HMGB1 via the RAGE and the
TLR-MyD88 pathways.
HMGB1-RAGE signaling is a distinct alternative signaling
pathway after acute brain injury
To control for potential confounding factors known for the used
stroke model of large brain lesion, we performed additional anal-
yses to investigate alternative explanations for the observed ef-
fects independent of the HMGB1-RAGE pathway. Previous
reports have demonstrated bacterial infections in this model,
which could have interfered with the immunological and behav-
ioral readout parameters investigated in this study. However, we
did not detect bacteria in lung homogenates or blood of any mice
(Fig. 7A). Furthermore, catecholamines released by activation of
the sympathetic autonomous nervous system have been reported
as mediators of poststroke immunosuppression (Prass et al.,
2003; Meisel et al., 2005). Therefore, we measured serum concen-
trations of glucocorticoid and catecholamine stress mediators in
WT control mice, anti-HMGB1 treated, and RAGE-deficient
mice after stroke without detecting significant differences among
groups (Fig. 7B). Next, we aimed to analyze the functional role of
catecholamine signaling on critical parameters affected by the
HMGB1-RAGE pathway in the previous experiments, such as
cytokine release, spleen cellularity, and MDSC expansion. There-
fore, we treated mice either with the 2-adrenoreceptor blocker
(b2-INH) ICI 118,551 (Mracsko et al., 2014), sRAGE. or the com-
bination of both. We observed that the inhibition of the RAGE
pathway by sRAGE-treatment, but not blockade of the adrener-
gic b2 receptor by b2-INH, abrogated the increased systemic
IL-6 secretion after brain ischemia (Fig. 7C). Both sRAGE
treatment and b2-INH injection prevented the expansion of
the CD11bLy-6C monocyte fraction (compare withFig. 5B).
However, b2-INH injection also caused a significant reduction in
this cell population compared with control-treated mice (Fig.
7D). On the other hand, the marked reduction of spleen cellular-
ity (Fig. 7E) was not affected by b2-INH but significantly abro-
gated by sRAGE treatment. Interestingly, the combination of the
RAGE as well as the catecholamine signaling had an additive
effect on this parameter. These results indicate that the HMGB1-
RAGE and the stress-mediator pathways might be largely inde-
pendent but differentially involved in specific signaling cascades,
such as acute cytokine release and immunosuppressive pathways.
4
Figure 5. Stroke induces immune exhaustion and expansion of immature monocytes via
HMGB1-RAGE signaling in the subacute phase after stroke. A, Representative FACS plots for
CD11b/Ly-6C expression of splenic mononuclear cells (CD45  gated) 3 d after sham or F-90 min
MCAO operation and the respective histogram for MHC-II expression of the double-positive cell
population. B, Cell count of myeloid-derived progenitor cells (CD11 Ly-6C MHC-II low) and
their proliferation (CD11b Ly-6C Ki-67 ) was analyzed in spleens at 24 h after sham oper-
ation or F90 min-MCAO with control (IgG) or anti-HMGB1 treatment (two left panels). Cell count
of CD11b Ly-6C  cells in the bone marrow was determined in the same groups (right panel).
Bars represent p  0.05 between indicated groups. C, Splenic CD11c  dendritic cells were
analyzed for CD80 and MHC-II expression at 3 d after sham operation (control) or MCAO. D,
Frequency of immature CD11 Ly-6C  monocytes was compared between WT and RAGE /
mice 3 d after F90 min-MCAO or sham surgery (n  6 per group). E, Splenic CD11c  dendritic
cells (1  10 5 cells) harvested from sham-operated animals and control antibody (IgG) or
anti-HMGB1 treated animals 3 d after MCAO were stimulated with 1 M CpG-ODN overnight,
and IL12p40 and TNF- cytokine concentrations were measured in the cell culture supernatant
(n  6 per group). B–E, Results are representative of at least two individual experiments per
set. F, Representative FACS dot plots for CD11b (top) and CD33/HLA-DR expression (gated for
CD11b , bottom) of total blood leukocytes (CD45  gated) from control or stroke patients. G,
Blood cell counts of immature CD11b CD33 monocytes (left) and their HLA-DR expression
were analyzed in control patients with no neurological disease or in stroke patients at 24 h after
extensive brain ischemia. H, Suppression assay analysis was performed to determine the sup-
pressive function of splenic CD11b Ly-6C  monocytes harvested from donor animals 24 h
after F90 min-MCAO (MDSC). T cells and MDSCs were cocultured at the indicated ratio and the
proliferation of CFSE-labeled T cells analyzed by FACS (shown as percentage of total CD3  T
cells). CD11b Ly-6C cells after MCAO are potent suppressors of T-cell proliferation. Data are
representative of 5 individual experiments. I, Representative plots with fitted peaks for cell
proliferation analysis by FlowJo software as used for MDSC suppression assay analysis shown
before. Labeling in the plot indicates MDSC:T-cell ratio. J, Representative Western blot images
(top) and analysis of ARG1 protein expression (bottom). ARG1 expression was measured in
isolated splenic CD11b  cells from sham-operated animals and control antibody (IgG) or anti-
HMGB1 treated mice 24 h after F90 min-MCAO. Analysis is depicted as normalized ARG1 density
values to actin expression. *p  0.05 (n  5 per group, 2 individual experiments).
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Discussion
This study presents data supporting a novel concept of brain-
immune interaction after acute brain lesions in which soluble
danger signals from the brain mediate a complex immunomodu-
latory reaction in the peripheral immune system. Previous stud-
ies have focused on the role of HMGB1 and other DAMPs on
immediate tissue injury within a defined organ, such as the heart
and the brain (Andrassy et al., 2008; Muhammad et al., 2008;
Shichita et al., 2012). This is the first study uncovering suprasys-
temic cross signaling via RAGE largely by cytokine-inducing iso-
forms of the soluble mediator HMGB1 released from the necrotic
brain. Our findings provide new insights into the peripheral im-
mune alterations in response to brain injury and propose brain-
released alarmins as important mediators of the systemic
Figure 6. HMGB1-RAGE signaling induces profound compromise of the peripheral adaptive immune system in the subacute phase after stroke. A, Representative images, mean weight, and
cellularity (SD) of spleens 3 d after sham operation or F90 min-MCAO in WT mice and RAGE / mice receiving control or anti-HMGB1 treatment (n  5–7 per group). MCAO induces a profound
reduction in spleen weight and cell count, which is significantly reversed in RAGE / mice. B, Flow cytometric analysis of absolute cell counts of Thelper (CD3
CD4 ), Tcytotoxic (CD3
CD8 ) cells
per spleen and (C) per microliter of whole blood in sham-operated animals and 3 d after F90 min-MCAO in WT and RAGE / mice receiving additional control IgG antibodies or anti-HMGB1
treatment. *p  0.05, between control animals of the same mouse strain and the indicated group. Bars represent p  0.05 between marked groups within the MCAO  groups. D, T-cell activation
was analyzed (CD69  right y-axis and CD25  left y-axis, respectively) in spleens of WT and RAGE / mice 3 d after MCAO (n  6 per group). E, The downstream signaling pathway of TLRs on
CD3  T cells was analyzed in MyD88 / mice. T-cell counts were measured per total spleen (left) and microliters of whole blood (right) in sham-operated animals and 3 d after F90 min-MCAO in
WT and MyD88 / mice treated with control or anti-HMGB1 antibodies. *p  0.05, between sham-operated animals of the same mouse strain and the indicated MCAO group. Bars represent p 
0.05 between marked groups within the MCAO groups.
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immune response leading to complex behavioral and metabolic
sequelae.
Our results are of clinical relevance for patients presenting
with severe acute brain injury because their prognosis is strongly
influenced by secondary immune-mediated complications. In
the early phase after clinical stroke and traumatic brain injury
features of sickness behavior, including sleep disorders, fatigue,
and depression, are common (Dantzer, 2006; Crosby et al., 2012),
which affect secondary morbidity and physical recovery (Willey
et al., 2010; Lerdal and Gay, 2013). The concept of proinflamma-
tory cytokines as the cause of clinical sickness behavior and pe-
ripheral inflammation is well established, and IL-1, IL-6, and
TNF- are seen as the main mediators (Dantzer et al., 2008).
These cytokines are also strongly upregulated in the periphery
during the acute phase after brain ischemia as shown in the pres-
ent and previous reports (Offner et al., 2006a; Chamorro et al.,
2012), but the underlying signaling and the resulting pathophys-
iological implications were unknown. In this study, we identified
the HMGB1-RAGE signaling pathway as the critical route induc-
ing this overshooting immune reaction after brain injury. Inhib-
iting this signaling pathway improved the systemic metabolic and
behavioral consequences of stroke and reduced mortality but did
not affect the size of the brain lesions. Similarly, direct neutral-
ization of the overshooting cytokine-release in the acute phase
after MCAO improved similar behavioral parameters, such as
circadian rhythm and mobility as for inhibition of the HMGB1-
RAGE pathway, supporting the concept of HMGB1-RAGE
mediated cytokine-induced behavioral alterations. Because
cytokine-induced sickness behavior is still not well established as
a distinct syndrome in the clinical setting and also requires more
comprehensive characterization in experimental models, future
studies will have to further validate this concept. Additionally, we
cannot exclude immediate modulatory effects of HMGB1-RAGE
signaling on brain structures that are not primarily affected by the
brain ischemia (e.g., hippocampus). Also, stress mediators,
which are released after acute brain injury, might have a currently
unknown direct impact on poststroke behavior mimicking
cytokine-induced sickness behavior (see below).
Immunosuppression predisposes patients to bacterial infec-
tions, which contribute substantially to poststroke morbidity
(Katzan et al., 2003). Based mainly on an experimental landmark
study using the  blocker propranolol (Prass et al., 2003), cat-
echolamines have been suggested as the key mediators of post-
stroke immune suppression and infectious complications
(Dirnagl et al., 2007; Iadecola and Anrather, 2011). Furthermore,
a previous study reported the modulation of hepatic iNKT cells
by noradrenergic signals after experimental stroke (Wong et al.,
2011). Indeed, most immune cells express catecholaminergic re-
ceptors and may undergo cell death after in vitro stimulation with
metanephrines, but blockade of  adrenergic receptor in vivo and
Figure 7. The HMGB1-RAGE pathway is distinct from infectious or catecholamine-mediated effects. A, Microbiological analysis of blood samples and lung homogenates 3 d after 90 min
Filament-MCAO for presence of bacteria. No significant growth of colony forming units (CFU) was detected after 24 h of incubation time on blood agar plates in any sample (n  21, 2 individual
experiments). B, Serum concentrations of cortisol and the catecholamines metanephrine and normetanephrine were measured 24 h after stroke induction (n  7 per group, 2 individual
experiments). Mice were treated with the 2-adrenoreceptor inhibitor ICI 118,551 (b2-INH) and/or sRAGE as indicated in Materials and Methods. C, sRAGE treatment, but not b2-INH, significantly
reduced plasma IL-6 concentrations 24 h after F90 min-MCAO. D, The expansion of CD11b Ly-6C MDSCs at 24 h after F90 min-MCAO was significantly reduced by sRAGE and, to a lesser extent, by
b2-INH and without a measurable additive effect. E, The reduction in spleen cellularity induced by MCAO was abrogated by b2-INH as well sRAGE treatment with an additive effect. C–E, Data were
obtained in three individual experiments; n  5 per group.
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in vitro fails to prevent lymphocytopenia, the hallmark of immu-
nodepression (Mracsko et al., 2014). Although increased cate-
cholamine blood levels have been reported after experimental
and clinical stroke (Chamorro et al., 2007; Urra et al., 2009b),
their correlation with lymphopenia, humoral immunosuppres-
sion or bacterial infections was not confirmed in a recent study in
stroke patients (Liesz et al., 2013a). Moreover, the catecholamin-
ergic concept of poststroke immune depression suggests the in-
Figure 8. Schematic overview of the proposed mechanisms of HMGB1 release and its biological activity after acute stroke. A, After acute vessel occlusion, cells of the hypoperfused territory become necrotic
andreleaseHMGB1(fullyreduced,hypoacetylated)fromitsnuclear localization.Between2and24hafter ischemiaonset,the(C23-C45)disulphide“cytokineHMGB1”becomesthepredominantHMGB1isoform.
B, Differential effects of HMGB1 in the spleen (left) and bone marrow (right) in the acute phase (24 h) after stroke. Splenic monocytes are activated via a RAGE-dependent pathway, producing increased
amounts of proinflammatory cytokines. In the bone marrow, HMGB1 induces proliferation of immature monocytes and their release to the circulation. C, The expanded population of (bone marrow-derived)
immature monocytes has features of myeloid-derived suppressor cells, which inhibit lymphocyte activation via arginase (ARG1) secretion and might induce lymphocyte apoptosis. Splenic and circulating APCs have an
“exhausted” phenotype characterized by reduced MHC-II expression and decreased cytokine production upon stimulation. Inadequate costimualtory signaling to lymphocyte induces T-cell dysfunction and might lead to
apoptosis.Additionally, increasedcatecholaminelevels inthesubacutephaseafterstrokeresult in impairedmonocytefunctionandlymphocytereductionprobably independentofHMGB1-RAGEsignaling.
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volvement of structures of the autonomic nervous system (e.g.,
the insula) and a laterality of the observed effect (right vs left
hemisphere). However, the evidence from clinical and experi-
mental studies rather points to lesion size instead of lesion loca-
tion as the primary determinator of immune depression
(Gendron et al., 2002; Hug et al., 2009; Liesz et al., 2013a). There-
fore, the link between acute ischemic brain injury and the impact
on the peripheral immune system remained to be identified. Ge-
netic or pharmacological blockage of pattern recognition recep-
tor signaling via HMGB1 and RAGE in this study abrogated
cellular immunosuppression and also restored the activation of
lymphocytes in the subacute phase after stroke. We have per-
formed experiments comparing the differential effects of inhib-
iting the RAGE signaling cascade and beta2-adrenergic signaling
on key outcome parameters of the acute immunostimulatory
phase (cytokine release) and the subsequent immunosuppres-
sive state in the subacute phase (spleen cellularity and MDSC
expansion). Our findings suggest that alarmin-mediated path-
ways and the poststroke stress-related catecholaminergic ef-
fects are largely independent. While brain-released alarmins
are released early after brain injury and might cause peripheral
immune activation and subsequent immune exhaustion, cat-
echolamines might represent an additional signaling pathway
in the subacute phase compromising poststroke immune
function (Fig. 8).
The concept of “stroke-induced immunodepression” (Meisel
et al., 2005; Dirnagl et al., 2007) has been perceived as an inde-
pendent and isolated immunological phenomenon after acute
brain injury. However, our results suggest that this immuno-
suppressive state in the subacute phase after stroke has to be
integrated as only one feature of the complex systemic immu-
nomodulation by disturbed brain-immune communication. We
detected a marked release of HMGB1 from the ischemic brain in
the hyperacute phase after the lesion. Mass spectrometric analysis
revealed a “maturation” of the post-translationally unmodified,
fully reduced isoform of HMGB1 toward the cytokine-inducing
isoform within the acute phase (Fig. 8A). For the cytokine-
stimulating function of HMGB1, its residues at C23 and C45
must form a disulfide bond, whereas the unpaired C106 within
BoxB must be in the reduced thiol state (Yang et al., 2010). This
isoform is a very strong stimulus for various types of immune
cells comparable with the stimulatory function of bacterial anti-
gens, such as LPS (Lotze and Tracey, 2005). In this study, we have
identified the induction of an “exhausted phenotype” of mature
splenic monocytes after the initial (over)activation of the periph-
eral immune cells by brain-released HMGB1 in the acute phase
(Fig. 8B,C). The induction of reduced responsiveness of mono-
cytes/macrophages to endotoxins or bacterial stimuli after a
strong inflammatory reaction has been described in immunolog-
ical conditions, such as sepsis or sterile inflammatory response
(Randow et al., 1995; Haupt et al., 1998; Cavaillon et al., 2005).
This hyporesponsive state of innate immune cells encompasses
the reduced expression of MHC and costimulatory molecules as
well as the impaired secretion of proinflammatory cytokines
(TNF- and IL-12). These features have also been reported after
brain ischemia (Hug et al., 2009; Urra et al., 2009b; Vogelgesang
et al., 2013). Inhibition of the initially overshooting immune ac-
tivation in the hyperacute phase by neutralizing HMGB1 inter-
action with its receptors ameliorated also the secondary
monocyte exhaustion, indicating a functional link between the
distinct and opposing immunological phenotypes observed in
the acute and subacute phase after brain lesion.
In addition to the exhaustion of mature monocytes, we de-
scribe here for the first time the HMGB1-induced expansion of a
monocyte subpopulation after stroke. This subpopulation has
features of MDSCs and contributes to the immunosuppressive
state in the subacute phase. However, the source of this expand-
ing population could not be determined with certainty. Our find-
ings suggest that it might arise from bone marrow egress, result
from peripheral expansion, or represent a mere phenotypical
change in the monocyte population. The phenotype of MDSCs
was previously identified in several disease models as
CD11bGr-1 cells, although distinct functional subsets have
meanwhile been characterized in different immunological mi-
lieus and disease models (Gabrilovich and Nagaraj, 2009). Al-
though a relative expansion of monocytes after stroke was noted
also in previous clinical and experimental studies (Vogelgesang et
al., 2008; Liesz et al., 2009, 2013a), the phenotypical and func-
tional characteristics of this expanding population had not been
analyzed so far. We detected a strong suppressive function of the
expanding CD11Ly-6C population on lymphocytes. Addi-
tionally, the expression of Arg1 was strongly increased in the
splenic monocyte population. Previous reports suggested a sup-
pressive and even toxic function of MDSCs on lymphocytes by
upregulation of Arg1, which induces apoptosis in activated lym-
phocytes by limiting the essential L-arginine concentration
needed for lymphocyte viability (Bronte et al., 2003; Rodríguez
and Ochoa, 2008). This novel finding of MDSC expansion and
increased Arg1 expression might be one mechanism explaining
the induction of lymphocytopenia after stroke, a key feature of
poststroke immunosuppression syndrome (Meisel et al., 2005).
Indeed, lymphocytopenia has been consistently described in this
study and previously in patients and experimental models of ex-
tensive brain lesions (Vogelgesang et al., 2008; Klehmet et al.,
2009; Urra et al., 2009a) and was found to be an independent
predictor of poststroke infections in patients (Liesz et al., 2013a).
The above-mentioned characteristics of lymphocyte-suppressing
MDSCs after stroke and the necessity of APCs for the stimu-
lation of T cells by HMGB1 demonstrated herein, suggest an
interaction of monocytes/APCs with lymphocytes down-
stream of the HMGB1-mediated pathways. However, the exact
molecular pathways underlying this potential monocyte/APC–
lymphocyte interaction after brain ischemia require further in-
vestigation. Furthermore, also other immunosuppressive cell
populations induced by the acute brain injury might be involved
in the observed peripheral immune alterations.
In conclusion, our data strongly suggest that HMGB1 release
from the ischemic brain and signaling through the pattern recog-
nition receptor RAGE is a key mechanism of the intricate periph-
eral immune response after brain injury that has profound
consequences on clinical outcome. Interfering with this pathway
may provide a promising therapeutic target for prevention of
immune-mediated complications of acute brain damage.
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Torres F, Planas AM (2007) Catecholamines, infection, and death in
acute ischemic stroke. J Neurol Sci 252:29 –35. CrossRef Medline
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4.2 Brain-released alarmins and stress response synergize in accelerating 
atherosclerosis progression after stroke. 
The risk for recurrent stroke is approximately 13 % in the first year after stroke and increases up to 30 
% within 5 years after the first ischemic event. Large-artery atherosclerosis (LAA) is the main cause 
for a first stroke and is also associated with the highest recurrence rate.  
Stroke induces a multiphasic, systemic immunomodulation in response to the acute brain injury. While 
the subacute immunosuppression after stroke has been well described to be a risk factor for secondary 
infections, the consequences of immune activation in the acute and chronic phase after stroke are 
barely investigated. The hypothesis was that systemic immune activation after stroke could impact 
inflammatory comorbidities of stroke patients such as atherosclerosis. We observed that stroke 
exacerbates atheroprogression via alarmin-mediated propagation of vascular inflammation. Activation 
of RAGE-signaling cascades by brain-derived alarmins such as high mobility group box 1 (HMGB1) 
induced monocyte and endothelial activation. Increase in vascular inflammation resulted in increased 
plaque load and plaque vulnerability after stroke. De novo recruitment of activated monocytes via the 
CCL2-CCR2 chemokine pathway to atherosclerotic lesions was a key event in stroke-induced vascular 
inflammation. Neutralization of circulating alarmins or a knockdown of RAGE ameliorated the post-
stroke atheroprogression. Pro-inflammatory mechanisms driven by brain-released alarmins synergized 
in their atherogenic effect with the stress-mediated, adrenergic mobilization of monocytes from the 
bone marrow after stroke. Blockage of β3-adrenoreceptors decreased the egress of myeloid monocytes 
after stroke, but only the neutralization of circulating alarmins reduced systemic monocyte activation 
and aortic invasion of activated monocytes.  
These findings identify the RAGE-signaling pathway as a critical mechanism leading to exacerbation 
of atheroprogression after stroke. Finally, these findings suggest the alarmin-RAGE pathway as a 
novel therapeutic target to prevent immunological comorbidities in stroke patients. 
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Brain-released alarmins and stress response synergize 
in accelerating atherosclerosis progression after stroke
Stefan Roth,1,2 Vikramjeet Singh,1,2 Steffen Tiedt,1,2 Lisa Schindler,1,2 Georg Huber,3 Arie Geerlof,3 
Daniel J. Antoine,4 Antoine Anfray,5 Cyrille Orset,5 Maxime Gauberti,5 Antoine Fournier,5 
Lesca M. Holdt,6 Helena Erlandsson Harris,7 Britta Engelhardt,8 Marco E. Bianchi,9 Denis Vivien,5 
Christof Haffner,1 Jürgen Bernhagen,1,2 Martin Dichgans,1,2 Arthur Liesz1,2*
Stroke induces a multiphasic systemic immune response, but the consequences of this response on atherosclerosis—a 
major source of recurrent vascular events—have not been thoroughly investigated. We show that stroke exacer-
bates atheroprogression via alarmin-mediated propagation of vascular inflammation. The prototypic brain-released 
alarmin high-mobility group box 1 protein induced monocyte and endothelial activation via the receptor for advanced 
glycation end products (RAGE)–signaling cascade and increased plaque load and vulnerability. Recruitment of 
activated monocytes via the CC-chemokine ligand 2–CC-chemokine receptor type 2 pathway was critical in 
stroke-induced vascular inflammation. Neutralization of circulating alarmins or knockdown of RAGE attenuated 
atheroprogression. Blockage of 3-adrenoreceptors attenuated the egress of myeloid monocytes after stroke, 
whereas neutralization of circulating alarmins was required to reduce systemic monocyte activation and aortic 
invasion. Our findings identify a synergistic effect of the sympathetic stress response and alarmin-driven inflam-
mation via RAGE as a critical mechanism of exacerbated atheroprogression after stroke.
INTRODUCTION
The risk of recurrent vascular events after stroke is high and remains 
elevated even years after first stroke (1, 2). The enhanced risk of sec-
ondary events encompasses large artery stroke and myocardial in-
farction, both manifestations of atherosclerosis (3, 4). Atherosclerosis 
is a chronic inflammatory condition of the arterial vessel wall, char-
acterized by an imbalance in lipid metabolism and recruitment of im-
mune cells leading to a chronic inflammatory milieu (5, 6). Key steps 
further include infiltration by monocytes, secretion of proteolytic en-
zymes, fibrous cap thinning, and plaque rupture, eventually causing 
end-organ damage due to ischemia. Previous work in experimental 
myocardial infarction has demonstrated an accelerating effect of this 
event on atheroprogression (7, 8), which has recently been linked to 
a stress-mediated mobilization of monocytes from bone marrow niches 
via adrenergic signaling (7). The same study further provided initial 
evidence for accelerated atheroprogression after experimental stroke 
(7). However, the mechanisms underlying enhanced atheroprogres-
sion after stroke have so far not been investigated.
Stroke promotes a multiphasic immunomodulation in the systemic 
immune compartment with an early sterile inflammatory response 
within hours and a chronic inflammatory response that is observed 
both in mice and in stroke patients (9–11). We previously demon-
strated that this systemic immunomodulation is triggered by alarmins 
released from necrotic brain tissue (12). This specifically involves the 
prototypic alarmin high-mobility group box 1 (HMGB1). Alarmins 
can have chemoattractant as well as cytokine-inducing properties 
and interact with pattern recognition receptors such as toll-like recep-
tors and the receptor for advanced glycation end products (RAGE) 
on various immune and nonimmune cell populations (13).
In light of these observations, we hypothesized that stroke might 
promote vascular inflammation and atheroprogression via an alarmin- 
driven systemic immune response. Here, we confirm exacerbation 
of atheroprogression after stroke and specifically identify a key role 
of the alarmin-RAGE pathway acting in synergy with the sympathetic 
stress response for de novo recruitment of activated monocytes to 
atherosclerotic lesions.
RESULTS
Stroke exacerbates atheroprogression via increased 
vascular monocyte recruitment
To determine the effect of stroke on exacerbation of atheroprogression, 
we fed 8-week-old apolipoprotein E–deficient (ApoE−/−) mice (14), 
a well-established mouse model for atherosclerosis, a high-cholesterol 
diet (HCD) for 8 weeks before the induction of experimental stroke 
and assessed plaque load after an additional 4 weeks of HCD (Fig. 1A 
and fig. S1). Overall plaque load in whole aorta was significantly (P = 
0.002) increased in mice undergoing stroke surgery compared to sham 
surgery as assessed by en face staining (Fig. 1B). Likewise, signifi-
cantly (P < 0.0001) increased plaque load was observed throughout 
the aortic valve (Fig. 1, C to E). Similar results were also obtained in 
female animals (fig. S2). To evaluate whether stroke-induced plaque 
formation was accompanied by vascular inflammation, we next per-
formed flow cytometric analysis of whole-aorta cell suspensions. In 
contrast to other immune cell populations (fig. S3), monocyte cell 
counts and, more specifically, the number of proinflammatory CD11b+ 
Ly6Chigh monocytes per aorta were increased after stroke compared 
to sham (Fig. 1, F and G). We further found an increase in the enzymatic 
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activity of matrix metalloproteinase 2 
(MMP2) and MMP9 as detected by in 
situ zymography (Fig. 1, H and I). Because 
increased MMP activity is associated with 
plaque instability (15), we further inves-
tigated morphological markers of vulner-
able plaques using previously established 
protocols (16). Cap thickness was reduced, 
and the number of highly unstable plaques 
increased in mice undergoing stroke sur-
gery compared to sham surgery, suggest-
ing a more vulnerable plaque morphology 
after stroke (Fig. 1J). Moreover, we ana-
lyzed plaques at the carotid bifurcation 
area, a predilected site for stenosis and pla-
 que rupture in stroke patients, observing 
also in this area a trend toward increased 
plaque load after stroke (fig. S4). To de-
termine whether the increased vascular 
inflammation was due to local prolifer-
ation or de novo recruitment of proin-
flammatory monocytes, we next implanted 
osmotic pumps releasing bromdeoxy-
urdine (BrdU) for detection of cell prolif-
eration. In addition, we intraperitoneally 
(ip) administered 1 × 107 CCR2RFP/+ re-
porter monocytes, expressing red fluores-
cent protein (RFP) under the CC- chemokine 
receptor type 2 (CCR2) promoter, for de-
tection of proinflammatory monocyte re-
cruitment in HCD-fed ApoE−/− mice after 
stroke or sham surgery (Fig. 2A). Although 
we found no difference in the prolifera-
tion rate of aortic monocytes/macrophages 
as assessed by BrdU incorporation (Fig. 2B 
and fig. S5), the recruitment of ip injected 
proinflammatory CCR2RFP/+ reporter cells 
into the aorta was substantially increased 
in stroke compared to sham group (Fig. 2, 
C and D, and fig. S6).
Stroke induces chemoattractant 
expression and  
endothelial activation
Next, we investigated the mechanisms 
underlying active aortic monocyte re-
cruitment after stroke and explored the 
possibility that stroke treatment may elicit 
a specific chemokine/cytokine profile in 
the atherogenic aorta. To investigate the 
aortic chemokine profile, we performed 
a polymerase chain reaction (PCR) array 
for 86 chemokines and chemoattractant 
receptors using lysates of whole aortas ob-
 tained 3 days after stroke or sham surgery 
(table S1). We found that the transcription 
of 12 chemokines and chemoattractant 
receptors was up-regulated after stroke 
compared to sham (Fig. 2E). Notably, the 
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Fig. 1. Stroke exacerbates atheroprogression. (A) Experimental design: Apolipoprotein E–deficient mice fed a 
high-cholesterol diet (HCD-fed ApoE−/−) underwent stroke or sham surgery and were sacrificed 1 month after surgical 
procedure. (B) Representative whole-aorta en face Oil Red O staining in sham and stroked mice (left) and quantification 
of the plaque load 1 month after stroke in sham and stroked animals (right, U test, n = 8 per group). (C) Representative 
images of Oil Red O–stained aortic valve sections 1 month after stroke or sham surgery. (D) Schematic representation 
of aortic valve. Red lines indicate the location of the sections analyzed in the study. (E) Quantification of aortic valve 
plaque load shown as percentage of plaque area per aortic valve in each section shown in (D) (left) and the area un-
der the curve (right, U test, n = 12 per group). (F) Representative gating strategy for flow cytometric analysis of aortic 
monocytes. SSC-A, side scatter area. (G) Flow cytometric analysis of whole-aorta lysates showing total monocytes 
(CD11b+; left) and the proinflammatory subset (Ly6Chigh; right) cell counts after stroke induction compared to sham 
(U test, n = 9 to 10 per group). (H) Representative images of aortic valve in situ zymography for 4′,6-diamidino- 
2-phenylindole (DAPI) (nuclear marker, blue) and matrix metalloproteinase 2/9 (MMP2/9) (representing enzymatical-
ly active areas, green) 1 month after surgery. (I) Quantification of MMP2/9 activity shown as enzymatically active area 
and normalized intensity (U test, n = 12 per group). (J) Representative images of Oil Red O–stained aortic valve sec-
tions 1 month after stroke (left) and quantification of number of plaque ruptures and cap thickness in aortic valve 
sections 1 month after sham or stroke surgery (U test, n = 14 to 15 per group). The arrowhead in the high-magnification 
image indicates a buried fibrous cap in lesion.
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most up-regulated chemokine was CC-chemokine lig-
 and 2 (CCL2), with a more than sixfold increase after 
stroke induction (fold change, 6.316; P = 0.018). 
CCL2 is secreted by foam cells in arterial lesions (17) 
and by activated endothelium (18) and attracts proin-
flammatory CCR2-expressing cells (19–21). Hence, we 
analyzed serum of mice after stroke and found increased 
CCL2 concentrations compared to sham-operated mice 
1 week after sham surgery (Fig. 2F). In addition, we 
measured monocytic CCR2 expression by flow cytom-
etry in aortas after stroke versus sham surgery, and we 
observed an increase in CCR2+ cell counts as well as 
CCR2 surface expression on inflammatory monocytes 
(Fig. 2G). One week after stroke induction, we detected 
fewer CD11b+Ly6Chigh RFP+ monocytes in the aortas 
of mice injected ip with homozygous CCR2RFP/RFP 
(CCR2-deficient) compared to heterozygous CCR2RFP/+ 
(CCR2-expressing) cells after stroke induction (Fig. 2H), 
indicating a critical role of the CCL2-CCR2 pathway in 
attraction of proinflammatory monocytes to the aorta 
after stroke.
Atherogenic monocyte recruitment is mediated by 
an orchestrated interplay of chemokine/chemokine 
receptor and integrin/adhesion molecule interactions 
with a pivotal role for endothelial activation. We found 
an increase mRNA expression of Icam1 and Vcam1, 
key adhesion molecules in atherogenic monocyte re-
cruitment, in aortas 3 days after stroke (Fig. 3A). In vivo 
molecular magnetic resonance imaging (MRI) using 
microsized particles of iron oxide–labeled vascular cell 
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Fig. 2. Stroke increases vascular inflammation via recruit-
ment of inflammatory monocytes to atherosclerotic plaques. 
(A) Schematic illustration of experimental design for data shown in 
(B) to (D): HCD-fed ApoE−/− mice underwent sham or stroke sur-
gery and received either continuous bromdeoxyurdine (BrdU) 
administration or CCR2RFP/+ bone marrow–derived cells intraperi-
toneally (ip). After 1 week, mice were sacrificed, and aortas and 
lymphoid organs were analyzed. (B) Analysis of BrdU+CD11b+ 
monocytes from aortas after stroke or sham surgery (U test, n = 5 
to 7 per group). (C) Gating strategy and representative histogram 
plots (right) for invading red fluorescent protein–positive (RFP+) 
monocytes in aortas (white, sham; gray, stroke) and (D) corre-
sponding quantification of RFP+CD11b+ monocytes in aorta (U test, 
n = 5 to 6 per group). (E) Fold change (FC) and adjusted P values 
(in parentheses) of chemokine and chemokine receptor tran-
scription in aorta lysates 3 days after stroke compared to sham 
surgery (left; n = 3 per group, P < 0.1) and corresponding volcano 
plot for transcriptional regulation determined by real-time poly-
merase chain reaction arrays (right panel; x axis = fold change; 
y axis = P value, cutoff at <0.1). (F) Serum levels of CC-chemokine 
ligand 2 (CCL2) 1 week after stroke compared to sham surgery 
(U test, n = 4 to 6 per group). (G) Flow cytometric analysis of aortic 
CCR2+Ly6Chigh monocytes (left) and CC-chemokine receptor type 
2–positive (CCR2+) surface expression on inflammatory Ly6Chigh 
monocytes (right) in aortas 3 days after stroke or sham surgery 
(U test, n = 7 per group). (H) Quantification of aortic invasion of 
adoptively transferred RFP-reporter cells from either CCR2-deficient 
(CCR2RFP/RFP) or CCR2+ RFP+ donor mice (CCR2RFP/+) (U test, n = 5 
to 6 per group).
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adhesion molecule–1 (VCAM-1)–specific antibodies (22) revealed 
an increase in VCAM-1 signal volume at 5 days after stroke in aortic 
valves compared to baseline values before stroke induction (Fig. 3, 
B to D). These experiments provided strong support for the activa-
tion of the aortic endothelium after stroke. We hypothesized that 
the observed endothelial activation was likely mediated by soluble, 
proinflammatory mediators released from the ischemic brain as pre-
viously described by our group (12). To test this hypothesis, we used 
an in vitro endothelial culture system, subjecting murine aortic en-
dothelial cells (MAECs) to stroke- or sham-conditioned plasma; con-
trol conditions included normal fetal calf serum–supplemented media 
with or without tumor necrosis factor– (TNF-) stimulation (Fig. 3E). 
We found that mRNA expression of Vcam1, Icam1, and Il6 increased 
after conditioning with stroke plasma compared to sham plasma, with 
expression similar to stimulation of MAECs by TNF- (Fig. 3F). More-
over, we found that addition of the soluble form of RAGE (sRAGE; 
10 ng/ml) decreased the expression of Vcam1, Icam1, and Il6 after 
stimulating the MAECs with stroke plasma. These results support 
the concept of poststroke endothelial activation by soluble plasma 
mediators such as cytokines and alarmins—druggable by decoy re-
ceptors such as sRAGE—with an ensuing active recruitment of mono-
cytes via CCR2-dependent pathways.
Poststroke alarmin release induces immune activation via 
the RAGE signaling pathway
Acute stroke leads to massive release of proinflammatory alarmins 
such as the prototypic alarmin HMGB1 from hypoxia-stressed and 
necrotic tissue (12). We confirmed the increase of plasma HMGB1 
concentrations acutely (24 hours) after experimental stroke and ex-
panded this observation to the chronic phase (30 days) when HMGB1 
plasma levels were still more than threefold elevated after stroke com-
pared to sham (Fig. 4A). We next reduced systemic alarmins in vivo 
using sRAGE as a decoy receptor for circulating alarmins (23). We 
treated mice 30 min before surgery and 4 hours after surgery with 
an intraperitoneal bolus (4 mg/kg) of sRAGE or vehicle and com-
pared monocytic activation and cytokine expression in whole-spleen 
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Fig. 3. Stroke induces inflammatory activa-
tion of the aortic endothelium. (A) Relative 
expression (RE) of Icam1 and Vcam1 transcrip-
tion in whole-aorta lysates 3 days after sham 
or stroke (U test, n = 5 per group). (B) Vascular 
cell adhesion molecule–1 (VCAM-1)–targeted 
iron particles were used for molecular mag-
netic resonance imaging (MRI) of endothelial 
activation in vivo before and after stroke. Rep-
resentative longitudinal and sagittal MRI im-
ages of aortic root area 5 days (5d) after stroke. 
(C) Representative comparison of the VCAM-1 
signal volume of the same aortic valve before 
and 5 days after stroke surgery. (D) Quantifica-
tion of VCAM-1 signal volume 5 days after stroke 
compared to baseline (U test, n = 5 per group). 
(E) Schematic illustration of experiments shown 
in (F). Wild-type (WT) mice received either stroke 
or sham surgery; 4 hours later, plasma was 
collected and used for conditioning media in 
murine aortic endothelial cell (MAEC) cultures. 
(F) RE of Icam1, Vcam1, and Il6 mRNA in MAECs 
after being incubated with stroke or sham plas-
ma and treated with soluble form of receptor 
for advanced glycation end products (sRAGE) 
(10 ng/ml) or vehicle (H test, n = 6 to 8 per 
group). For control conditions, fetal calf serum 
(FCS)–supplemented media without cytokine 
stimulus or with recombinant tumor necrosis 
factor– (TNF-; 20 ng/ml) were used. *P < 0.05, 
**P < 0.01, ***P < 0.001.
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lysates 3 days after stroke. Compared to sham-operated mice, mice 
undergoing stroke surgery showed an increase of major histocom-
patibility complex class II (MHCII) expression as a monocytic activa-
tion marker (Fig. 4B) and elevated Il6 and Tnfa mRNA expression 
(Fig. 4C). In contrast, sRAGE treatment abrogated the increase in 
MHCII expression and cytokine mRNA expression after stroke (Fig. 4, 
B and C). To investigate the role of soluble plasma mediators in mono-
cyte activation more specifically, we treated primary monocyte cul-
tures with recombinant HMGB1 or conditioned medium with plasma 
from sham-operated or stroked mice. Analysis of the mRNA expres-
sion revealed a dose-dependent increase in Il6 and Tnfa expression 
after treatment with recombinant endotoxin-free HMGB1 as well as 
plasma from stroked animals, confirming a key role for soluble me-
diators such as HMGB1 in the activation of monocytes (Fig. 4D). 
Accordingly, we also detected substantially increased serum HMGB1 
concentrations in human stroke patients both in the acute (within 
first 48 hours) and subacute phase (72 hours and 7 days) (Fig. 4E and 
table S2). Analysis of the different human HMGB1 reduction/oxidation 
(redox) forms by mass spectroscopy identified the functionally rel-
evant cytokine-inducing disulfide HMGB1 isoform as the predom-
inant modification after 3 days after stroke (Fig. 4E). This finding 
is in accordance with our previous observations on HMGB1 redox 
modifications in experimental stroke in mice showing that disulfide 
HMGB1 is the key mediator resulting in activation and expansion of 
the systemic monocyte population after stroke (12, 24, 25). The in-
crease of proinflammatory HMGB1 was reflected in the pattern of 
transient leukocytosis during the time course after stroke (Fig. 4F). 
Moreover, C-reactive protein blood levels and neutrophil counts were 
increased after stroke, reflecting the alarmin-driven sterile inflam-
matory response (fig. S7). Accordingly, we also detected an increase 
in the frequency of activated human leukocyte antigen (HLA- DR+) 
cells 2 months after human stroke (Fig. 4G).
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Fig. 4. HMGB1 induces systemic innate immune activation after stroke. (A) Plasma high-mobility group box 1 (HMGB1) concentrations were measured by enzyme-linked 
immunosorbent assay in naïve, sham, and stroke HCD-fed ApoE−/− mice 1 and 30 days after surgery [one-way analysis of variance (ANOVA), n = 7 to 9 per group). (B) Flow 
cytometric analysis of major histocompatibility complex class II–positive (MHCII+) expression of splenic myeloid cells from HCD-fed ApoE−/− mice 3 days after stroke with 
vehicle or sRAGE treatment (one-way ANOVA, n = 8 per group). (C) RE of Il6 and Tnfa mRNA in spleen of sham-operated and stroked vehicle-treated or sRAGE-treated WT 
mice 3 days after surgical procedure (H test, n = 6 per group). (D) RE of Il6 and Tnfa mRNA of isolated murine splenic monocytes from WT mice, which were stimulated with 
recombinant HMGB1 (0.1 and 0.5 g/ml), murine sham and stroke plasma (50%), and lipopolysaccharide (LPS) (0.1 g/ml) in vitro (H test, n = 5 to 8 per group). (E) Plasma 
concentration of HMGB1 acquired by quantitative mass spectrometry analysis at different time points (days 1 to 7) in stroke patients and age-matched controls (C; left; 
n = 15 to 18 per group, one-way ANOVA). Changes in the distribution of HMGB1 reduction/oxidation (redox) state from fully reduced to disulfide state over the first week 
after stroke (right; n = 15 to 18 per group). (F) Quantification of blood leukocyte counts in ischemic stroke (IS) and control patients (n = 15 to 18 per group). (G) Flow cyto-
metric analysis of human patient blood samples for human leukocyte antigen (HLA-DR+) cell count as an indication of monocyte activation at up to 60 days after large IS 
compared to age-matched controls (t test, n = 12 to 17 per group). *P < 0.05, **P < 0.01, ***P < 0.001.
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In light of the effective abrogation of the poststroke systemic im-
mune response in the presence of sRAGE, we aimed to test the effect 
of sRAGE treatment on stroke-induced atheroprogression. Athero-
sclerotic animals were treated before and after surgery with an intra-
peritoneal bolus (4 mg/kg) of sRAGE, and aortic plaque load was 
analyzed after sham or stroke surgery (Fig. 5A). We found reduced 
plaque loads in aortas of mice receiving sRAGE compared to control- 
treated mice after stroke, whereas no difference was detected for the 
sham-operated groups between control and sRAGE treatment (Fig. 5B). 
Correspondingly, the overall survival rate and normalization of post-
stroke weight loss were improved in sRAGE- treated animals (fig. S8), 
and the same pattern of treatment efficacy was observed for the plaque 
load in aortic valves (fig. S9). In addition, flow cytometric analysis 
revealed that sRAGE abrogated poststroke increase in total CD45+ 
CD11b+ as well as CD11b+Ly6Chigh proinflammatory mono cyte cell 
counts in aortas 4 weeks after stroke induction (Fig. 5C). Assessment 
of the lipid profiles of HCD-fed ApoE−/− mice revealed no differences 
after stroke induction and sRAGE treatment, except for the nonath-
erogenic (26) triglyceride levels (fig. S10).
Given the potent effect of sRAGE on neutralizing the effects of 
poststroke alarmins on vascular inflammation and atheroprogres-
sion, we aimed to more specifically investigate the contribution of the 
RAGE-dependent pathway. To down- regulate RAGE in vivo, we ad-
ministered RAGE-specific small interfering RNA (siRNA) in HCD-
fed ApoE−/− mice and found a knockdown of aortic RAGE mRNA and 
protein expression 3 days after hydrodynamic intravenous siRNA 
injection of 10 nmol of RAGE- silencing or negative control siRNA 
(Fig. 5, D and E). siRNA-induced RAGE knockdown reduced aortic 
total and proinflammatory monocyte counts 7 days after stroke induc-
tion compared to control treatment with unspecific siRNA (Fig. 5F). As 
RAGE also engages lig ands other than HMGB1, we next aimed to test 
the specific contribution of HMGB1 as a potential mediator leading to 
RAGE-mediated atheroprogression. Neutralizing circulating HMGB1 
by intraperitoneal injection of HMGB1-specific monoclonal anti-
bodies (4 mg/kg) immediately after experimental ischemia attenu-
ated the increase in cellular vascular inflammation after stroke in-
duction (Fig. 5G). However, neither infarct volume nor behavioral 
deficits were affected by the sRAGE or HMGB1-specific antibody treat-
ment compared to control treatment 1 week after experimental stroke. 
Moreover, using HMGB1-specific antibodies in wild-type (WT) mice 
reduced monocyte expansion and activation in blood and increased cell 
number in spleen 24 hours after stroke (fig. S11). To further elaborate 
on the role of HMGB1 as a proinflammatory mediator of atheropro-
gression, we administered recombinant HMGB1 to HCD-fed ApoE−/− 
mice without any surgical intervention. We found increased monocyte 
counts in whole-aorta lysates (Fig. 5H) and exacerbated plaque loads 
in aortic valves 7 days after HMGB1 injection (Fig. 5, I and J). In ad-
dition, we detected an up- regulation of Il6, Icam1, and Vcam1 mRNA 
expression in whole-aorta lysates (fig. S12), resembling the proinflam-
matory expression pattern found in aortas of mice undergoing stroke 
(compared to Fig. 3A). Together, these results indicate that HMGB1—
and potentially other alarmins released from the necrotic brain tissue—
induces a sterile, systemic immune response via vascular RAGE, which 
in turn results in exacerbation of vascular inflammation after stroke.
Alarmin release and sympathetic stress response synergize 
in poststroke atheroprogression
We aimed to further dissect the differential contribution of the sym-
pathetic innervation versus alarmin-driven cascades on the observed 
effects of systemic immune activation and vascular inflammation after 
stroke. In accord with earlier findings (27), we observed a decrease 
in overall myeloid cell count of the femur bone marrow at 24 hours 
after stroke (Fig. 6A). This was associated with an increase in tyrosine 
hydroxylase expression along sympathetic fibers in the femur bone 
marrow (Fig. 6, B and C). These results indicated a potential release 
of monocytes from the bone marrow after sympathetic innervation 
due to a stroke-induced stress response. We and others previously 
observed a splenic expansion of myeloid cells after stroke induction 
(12, 28). Hence, we tested the possibility of myeloid cell trafficking 
from the bone marrow to the spleen after stroke using an in vivo 
cell-tracking approach. After in vivo labeling of the bone marrow by 
quantum dot (Qdot) nanocrystals—nanometer-scaled fluorophores 
incorporated in the cytoplasm of living cells—we found an increased 
number of Qdot+ monocytes in spleen after stroke compared to sham 
surgery (Fig. 6, D and E), whereas the Qdot+ cell count in bone marrow 
decreased after stroke (fig. S13). To further investigate the contribution 
of the splenic immune compartment to poststroke vascular inflam-
mation, we performed splenectomy versus sham surgery in HCD-
fed ApoE−/− mice before stroke induction in both groups. Seven days 
after stroke, we found reduced aortic monocyte counts in splenecto-
mized animals and a decreased plaque load in aortic valves compared 
to the nonsplenectomized but stroked control group (Fig. 6, F and G); 
however, splenectomy had no effect on infarct severity or bone mar-
row monocyte count (fig. S14). Together, these findings suggest a role 
for sympathetic innervation in mobilization of myeloid cells from the 
bone marrow niche as well as maturation/activation of monocytes 
in the splenic immune compartment, thus contributing to stroke- 
induced atheroprogression.
To further test this hypothesis, we analyzed the differential contri-
bution of the alarmin signaling cascade and sympathetic innervation 
on monocyte cellularity and activation using sRAGE decoy receptors 
and the 3-adrenoreceptor inhibitor SR59230A (7, 29). Blocking 
3- adrenoreceptors but not sRAGE treatment suppressed the egress 
of CD11b+CD45+ monocytes from the bone marrow, whereas both 
treatment regimens increased overall spleen cellularity (Fig. 6, H 
and I). Notably, 3-adrenoreceptor blockage did not alter HMGB1 
plasma concentrations after stroke (fig. S15). sRAGE treatment ab-
rogated monocyte activation in the spleen after stroke, whereas ad-
renoreceptor blockage affected MHCII up-regulation only when 
applied in combination with sRAGE (Fig. 6J). In blood, we observed 
similar treatment effects with only the combination of adrenorecep-
tor and sRAGE blockage being effective in decreasing monocyte 
activation (fig. S16). We further investigated synergistic effects of 
neutralizing sympathetic activation and alarmin neutralization on 
exacerbation of vascular inflammation after stroke. Although both 
treatments attenuated the increase in aortic monocyte counts after 
stroke, blocking of alarmin signaling using sRAGE was required to 
attenuate the increase in activated MHCII+ monocytes in athero-
sclerotic lesions after stroke (Fig. 6K). We additionally analyzed the 
impact of adrenoreceptor and sRAGE blockage on aortic valve plaque 
load. In accordance with the synergistic effects of adrenoreceptor 
and sRAGE blockage on inflammatory markers of vascular inflam-
mation, only the combined treatment was effective in reducing aortic 
plaque load compared to the control treatment (Fig. 6L). These re-
sults suggest that sympathetic activation during the acute stress re-
sponse after stroke drives bone marrow egress of monocytic cells, 
whereas brain-released alarmins are required for monocyte activa-
tion (fig. S17).
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DISCUSSION
Large-artery atherosclerosis is a major cause of stroke that is also 
associated with an unexpectedly high recurrence rate (1, 2). We have 
shown that experimental stroke induces exacerbation of atheropro-
gression. Enhanced vascular inflammation after stroke depended on 
a synergistic effect of sympathetic recruitment of monocytes from the 
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Fig. 5. Stroke induces atheroprogression via the RAGE-signaling pathway. (A) Schematic illustration of experimental design for data shown in (B) to (D): HCD-fed 
ApoE−/− mice received either an intraperitoneal injection of sRAGE or vehicle treatment 30 min before and 4 hours after the respective surgery and were sacrificed 1 month 
later. (B) Quantification of the overall plaque area per aorta 1 month after surgery in stroke or sham mice treated with sRAGE or vehicle (ANOVA, n = 8 per group). (C) Flow 
cytometric analysis of whole aorta for CD11b+ and CD11b+Ly6Chigh monocyte counts after stroke with sRAGE or vehicle treatment compared to sham-operated mice 
1 month after surgery (H test, n = 7 to 8 per group). (D) RAGE mRNA expression 3 days after hydrodynamic intravenous injection of RAGE-specific small interfering RNA 
(siRNA) or control siRNA (Ctrl; U test, n = 5 per group). (E) RAGE protein expression 3 days after RAGE-specific or control siRNA injection (n = 3 per group). (F) HCD-fed 
ApoE−/− mice received stroke or sham surgery 3 days after hydrodynamic RAGE-specific or control siRNA injection and were sacrificed 7 days later for flow cytometric 
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to HCD-fed ApoE−/− mice (U test, n = 7 to 8 per group). (I) Representative images of Oil Red O stained aortic valve sections 7 days after rHMGB1 administration. (J) Com-
parison of Oil Red O+ area on five consecutive sections in aortic valves (left). Area under the curve analysis of the individual aortic valves (right) after HMGB1 administration 
compared to control-treated naïve ApoE−/− mice (U test, n = 7 per group). *P < 0.05, **P < 0.01.
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bone marrow niche and subsequent ac-
tivation of innate immune and endothe-
lial cells by circulating alarmins, attracting 
inflammatory monocytes to atherosclerotic 
lesions. We further identified the HMGB1- 
RAGE pathway as a critical signaling mech-
anism eliciting the sterile inflammatory 
response after stroke.
We observed a rapid translocation of 
bone marrow monocytes to the spleen 
after stroke. Myeloid monocyte mobili-
zation has previously been shown to be 
critically mediated by sympathetic sig-
naling via 3-adrenoreceptors in myocar-
dial infarction models (27). Accordingly, 
we showed an important role of 3- 
adrenoreceptors in stroke-induced mono-
cyte mobilization using specific inhibitors. 
However, although blocking sympathetic 
innervation attenuated monocyte eva-
sion from the bone marrow, it did not 
affect monocyte activation, vascular in-
flammation, or plaque growth. Notably, 
previous studies in experimental and 
clinical stroke have associated the sym-
pathetic stress response with subacute 
im munosuppression but not monocyte 
activation or vascular inflammation (30). 
Hence, our results strengthen the con-
cept of a second mechanism promoting 
the inflammatory response after stroke, 
independent of sympathetic activation.
Aside from eliciting a local immune 
response with microglial activation, the 
release of HMGB1 and other alarmins 
from necrotic brain tissue induces a sys-
temic response with cellular activation 
and massive cytokine secretion in periph-
eral immune organs (10, 12). Systemic 
immune activation involves a rapid ster-
ile immune response acutely after stroke, 
followed by an immunosuppression dur-
 ing the subacute phase (days 2 to 7) af-
ter stroke. In addition, previous clinical 
studies have demonstrated a third phase 
characterized by a delayed chronic im-
mune activation (from day 7 on) with 
elevated inflammatory markers for more 
than 1 year after stroke in patients (9, 31). 
The biological activity of HMGB1 de-
pends critically on its redox state (32, 33). 
Fully reduced HMGB1 has chemoattract-
ant properties, whereas disulfide HMGB1 
has cytokine-inducing properties and the 
terminally oxidized sulfonyl HMGB1 is 
anti-inflammatory (11). We observed that 
HMGB1 levels in stroke patients not only 
remained substantially increased during 
the first week after stroke but that the 
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Fig. 6. Alarmin release and sympathetic stress response synergize in poststroke atheroprogression. (A) Flow 
cytometric analysis of myeloid cellularity in femur bone marrow 24 hours after stroke compared to sham surgery. (B) Rep-
resentative images of immunofluorescence staining for tyrosine hydroxylase (TH) in femoral bone marrow 24 hours 
after stroke and sham surgery. (C) Quantification of TH+ area after stroke compared to sham on femoral sections (U test, 
n = 7 per group). (D) WT mice received quantum dot (Qdot) nanocrystal injections in the femoral bone marrow 2 hours 
before stroke or sham surgery and were sacrificed 24 hours later (U test, n = 6 per group). Representative gating strat-
egy for CD45+CD11b+ monocytes and Qdot+ myeloid cells in spleen after stroke or sham surgery. (E) Quantification 
of total Qdot+ myeloid cells in spleens after stroke compared to sham surgery (U test, n = 5 per group). (F) HCD-fed 
ApoE−/− mice were splenectomized (Splenect.) before stroke or sham surgery and analyzed 7 days after stroke for 
total monocyte cell counts and proinflammatory Ly6Chigh frequency in aortas 1 week after stroke. (G) Quantification 
of overall plaque area in aortic valves of splenectomized mice after stroke induction (U test, n = 6 to 8 per group). (H to 
J) WT mice received either sRAGE, 3-blocker SR59230, both combined, or vehicle treatment immediately after stroke, 
and bone marrow (BM) (H) and spleen (I and J) were analyzed by flow cytometry 24 hours later for the total myeloid 
(CD45+CD11b+) cell count and monocyte activation (percentage of MHCII+ monocytes; H test, n = 6 to 8 per group). 
(K) HCD-fed ApoE−/− mice received sRAGE, SR59230, combination therapy, or control treatment immediately after 
stroke. Bar graphs represent the flow cytometric analysis of CD45+CD11b+ monocyte cell count, the percentage of 
MHCII+ monocytes, and Ly6Chigh monocytes in aortas 1 week after stroke (H test, n = 7 to 8 per group). (L) Area under 
the curve analysis quantifying plaque load in five consecutive sections of aortic valve for HCD-fed ApoE−/− mice (H test, 
n = 5 to 6 per group). *P < 0.05, **P < 0.01.
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proinflammatory disulfide HMGB1 species became the predominant 
isoform over this time course.
Monocytes/macrophages play a critical role in the development 
and propagation of atherosclerotic lesions. Monocyte invasion into 
atherogenic lesions has been shown to be instrumental in the initi-
ation of atherosclerosis. In this phase, the chemokine-ligand recep-
tor interaction plays a pivotal role. Studies have shown that CCR2 
expression on monocytes is essential for recruitment into the adven-
titial space and for further plaque development (34, 35). In contrast, 
proliferation of macrophages has been demonstrated to be the key 
driver for lesion growth in established atherosclerosis (36). Surpris-
ingly, we observed that poststroke exacerbation of established athero-
sclerotic lesions was associated with enhanced de novo recruitment 
of circulating monocytes to the vessel rather than increased local pro-
liferation. A possible explanation for this phenomenon is that as a 
consequence of the strong inflammatory response after stroke, mono-
cyte chemoattraction via the CCL2-CCR2 axis regains a predominant 
role for monocyte recruitment comparable to the initiation of the vas-
cular inflammatory milieu (37). Aside from chemoattraction, endo-
thelial expression of adhesion molecules is pivotal for monocyte 
recruitment. Intercellular adhesion molecule–1 (ICAM-1) and VCAM-1 
are known to be essential for the arrest and extravasation of mono-
cytes into the arterial wall (38). Our data unequivocally demonstrate 
the up-regulation of these critical adhesion molecules on aortic en-
dothelial cells in mice by PCR, in vivo imaging, and in vitro cultures. 
In accord with our results, it was previously shown that HMGB1 
can activate endothelial cells, leading to changes in the nuclear fac-
tors Sp-1 and nuclear factor B, with subsequent up-regulation of ad-
hesion molecules and proinflammatory cytokines (18).
We observed a highly consistent effect of poststroke exacerbation 
of atherosclerosis pathology both in female and male mice, in aortas 
and aortic valves, and verified this phenomenon by in vivo MRI. How-
 ever, a limitation of this study is that we were not able to fully inves-
tigate the link between poststroke atheroprogression and enhanced 
plaque rupture as a cause of recurrent stroke in the mouse athero-
sclerosis model. Atherosclerotic lesions of aorta and large arteries in 
animal models, including the ApoE-deficient model used here, rarely 
develop spontaneous destabilization and rupture with occlusive vas-
cular thrombosis. We observed several surrogate markers of increased 
plaque vulnerability; however, increased incidence of plaque rupture 
and secondary ischemic brain lesions will have to be tested in more 
specific models that mimic human plaque rupture and ultimately in 
prospective clinical studies.
In conclusion, our data identify stroke-induced alarmin release 
from the ischemic brain as a critical mechanism activating inflam-
matory pathways and acting in synergy with an acute stress response 
after stroke to exacerbate atherosclerosis. Interfering with this sterile 
immune response by neutralizing brain-released alarmins may pro-
vide a therapeutic approach for stroke patients.
MATERIAL AND METHODS
Study design
The goal of this study was to investigate atheroprogression after stroke 
and describe the underlying mechanisms in an experimental model of 
ischemic stroke in ApoE−/− mice. Sample sizes were calculated using 
GPower 3.1. On the basis of a previous report (7), we used a monocyte 
increase rate of 40% with an SD of 25%. Using an  error of 0.05 and 
power of 0.8, we calculated a group size of 8 (t test, two groups, unpaired).
Data were excluded from all mice that died during surgery. De-
tailed exclusion criteria for the experimental models were (i) insuf-
ficient middle cerebral artery (MCA) occlusion (blood flow reduction 
less than 80%), (ii) death during surgery, and (iii) lack of brain ischemia 
as quantified by histology (see table S3 for included/excluded animals 
per experiment). Animals were randomized to treatment groups, and 
all analy ses were performed by investigators blinded to group alloca-
tion. Unblinding was performed after completion of statistical analysis. 
All animal experiments were performed and reported in accordance with 
the Animal Research: Reporting of In Vivo Experiments (ARRIVE) 
guidelines (39).
Experimental animals
All animal experiments were performed in accordance with the guide-
 lines for the use of experimental animals and were approved by the 
government committee of Upper Bavaria (Regierungspraesidium 
Oberbayern, #175-2013). We used age-matched, male C57BL6/J mice 
(8 to 10 weeks, 22 to 24 g body weight; Charles River Laboratories). 
ApoE−/− (the Jackson Laboratory) mice were fed an HCD (#88137, 
ssniff). Transient filament occlusion was performed in all ApoE−/− 
after 8 weeks of HCD. CCR2-RFP knock-in mice were bred with 
CX3CR1–green fluorescent protein (GFP) mice (40).
Clinical stroke patient study population
Ischemic stroke patients were recruited within 24 hours of symptom 
onset. All patients had a final diagnosis of ischemic stroke as defined 
by an acute focal neurological deficit in combination with a diffusion- 
weighted imaging-positive lesion on MRI or a new lesion on a de-
layed computed tomography scan. Age- and comorbidity- matched 
patients without neurological disease were used as controls. The study 
was approved by the local ethics committee and was conducted in 
accordance with the Declaration of Helsinki and institutional guide-
lines. Written and informed consent was obtained from all subjects.
Statistical analysis
Data were analyzed using GraphPad Prism version 6.0. All summary 
data are expressed as means ± SD. All data sets were tested for normal-
ity using the Shapiro-Wilk normality test. The groups containing 
normally distributed data were tested using a two-way Student’s t test 
(for two groups) or analysis of variance (ANOVA) (for more than 
two groups). The remaining data were analyzed using the Mann- 
Whitney U test (for two groups) or H test (for more than two groups). 
Similar variance was assured for all groups, which were statistically 
compared. Differences with a P < 0.05 were considered to be statistically 
significant. P values were adjusted for comparison of multiple com-
parisons using Bonferroni correction.
SUPPLEMENTARY MATERIALS
www.sciencetranslationalmedicine.org/cgi/content/full/10/432/eaao1313/DC1
Materials and Methods
Fig. S1. Characterization of the 60-min filament MCA occlusion (fMCAo) model.
Fig. S2. Exacerbation of atherosclerotic lesions in aortic valves of male and female HCD-fed 
ApoE−/− mice 1 month after fMCAo surgery.
Fig. S3. Immune cell counts in aorta of HCD-fed ApoE−/− mice 1 month after experimental 
stroke.
Fig. S4. Analysis of atherosclerotic plaque load at the common carotid artery bifurcation in 
HCD-fed ApoE−/− mice.
Fig. S5. Comparison of BrdU incorporation in aorta, blood, and spleen 1 week after 
experimental stroke surgery.
Fig. S6. RFP+CD11b+ cell counts in blood after experimental stroke surgery.
Fig. S7. Immunological data of stroke patients.
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Fig. S8. Body weight and mortality in sRAGE treatment mice after stroke.
Fig. S9. Atherosclerotic lesions in aortic valves of male and female HCD-fed ApoE−/− mice  
1 month after experimental stroke and sRAGE treatment.
Fig. S10. Lipid profile of plasma samples 1 month after experimental stroke surgery and sRAGE 
treatment.
Fig. S11. Flow cytometric analysis of spleen and blood 24 hours after experimental stroke with 
anti-HMGB1 treatment.
Fig. S12. Recombinant HMGB1 in vivo administration exacerbates atherosclerosis.
Fig. S13. Quantification of in vivo Qdot labeling of femoral bone marrow 24 hours after 
experimental stroke.
Fig. S14. Myeloid cell count in femoral bone marrow and brain infarct volumetry after 
splenectomy.
Fig. S15. Impact of 3-adrenoreceptor blockage on HMGB1 plasma levels after experimental 
stroke.
Fig. S16. Impact of 3-adrenoreceptor blockage (SR59230A), alarmin blockage (sRAGE), and 
combined treatment on blood immune cells in WT mice.
Fig. S17. Schematic overview of proposed mechanism of atheroprogression after stroke.
Table S1. Primer list for quantitative PCR array (mouse chemokines and receptors).
Table S2. Demographic and clinical characteristics of the study population.
Table S3. Number of (excluded/included) animals in accomplished experiments.
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interfering with these processes after stroke might reduce the risk of secondary cardiovascular events.
exert a synergistic effect, resulting in exacerbation of atherosclerotic plaques in mice. The authors suggest that
stroke-induced alarmin high-mobility group box 1 (HMGB1) release and sympathetic stress response activation 
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models have shown accelerated atherosclerosis after stroke; however, the mechanisms underlying this enhanced 
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Materials and Methods 
Transient ischemia-reperfusion stroke model. Mice were anaesthetized with isoflurane 
delivered in a mixture of 30% O2 and 70% N2O. An incision was made between the ear and 
the eye in order to expose the temporal bone. A laser doppler probe was affixed to the skull 
above the middle cerebral artery (MCA) territory, and the mice were placed in supine 
position. A midline neck incision was made and the common carotid artery and left external 
carotid artery were isolated and ligated; a 2-mm silicon-coated filament (Doccol) was 
introduced via a small incision in the common carotid artery and inserted into the internal 
carotid artery, finally occluding the MCA which was confirmed by a corresponding decrease 
in blood flow (decrease in the laser doppler flow signal <20% of baseline value). After 60 
minutes of occlusion, the animals were re-anesthetized, and the filament was removed. After 
recovery, the mice were kept in their home cage with facilitated access to water and food. 
Sham-operated mice received the same surgical procedure, except the filament was inserted 
and immediately removed, after 60 minutes mice were re-anesthetized. Body temperature was 
maintained at 37°C throughout surgery using a feedback-controlled heating pad. The overall 
mortality rate in this group (excluding the Sham-operated animals) was approximately 20 %. 
Exclusion criteria: 1. Insufficient MCA occlusion (a reduction in blood flow to >20% of the 
baseline value). 2. Death during the surgery. 3. Lack of brain ischemia as quantified post-
mortem by histological analysis. A stroke assessment score was acquired 1 hour after 
reperfusion. For scoring the animal after surgical procedure a score from 0 (no stroke) to 5 
(very severe stroke) based on general activity and body asymmetry was used (“modified 
Bederson Score”) (41). 
Splenectomy. Mice were anaesthetized with isoflurane delivered in a mixture of 30% O2 and 
70% N2O. A dorsal incision was made lateral to the spine and the abdominal cavity was 
entered. Blood vessels were ligated and spleen was removed by transecting the vessels distal 
to the ligature. Body temperature was maintained at 37°C throughout surgery using a 
feedback-controlled heating pad. Mice were kept under controlled conditions until they were 
fully recovered from anesthesia. 
Soluble mouse RAGE production. Soluble RAGE recombinant baculovirus was a kind gift 
from Dr. Ann-Marie Schmidt (New York University Langone Medical Center, USA). sRAGE 
recombinant virus was propagated in Sf21-cells and supernatant was kept at 4°C for further 
analysis and protein production. Low passage viral titer was determined by quantitative PCR 
(42). For protein production, Sf21 cells were seeded one day prior to infection with 1x106 
cells/mL. Cells were infected and incubated at 27°C. Three days later, supernatant (SN) was 
harvest, filtered and buffer exchanged to 0.1 PBS pH 6.9/50mM NaCl. sRAGE was captured 
by ion-exchange chromatography using a CaptoS-5mL prepacked column (GE Healthcare) 
and eluted with 0.1xPBS, pH 6.9/600mM NaCl. Positive fractions were pooled, diluted 15-
fold in 0.1PBS pH6.9/50mM NaCl and purified by ion-exchange chromatography using a 
ResourceS-1mL prepacked column (GE Healthcare). Positive fractions were pooled, dialyzed 
against PBS, pH 7.2, 10% glycerol at 4°C and stored at -80°C.  
Drug & dye administration.  
sRAGE: Mice received intraperitoneally three injections of sRAGE (Helmholtz), 30 min 
before, 24 h and 2 weeks after surgery. sRAGE was injected i.p. at a dose of 3.5 mg kg-1 body 
weight in a final volume of 100 µl.  
HMGB1: Mice received one bolus (100µg) of either anti-HMGB1 or isotype control IgG 
immediately after ischemia induction. The anti-HMGB1 antibody (m2G7, IgG2b) does not 
recognize HMGB2 and binds to the amino acids 53-63 within the box A domain of rodent and 
human HMGB1 (43) and was purified from hybridoma supernatant by protein G affinity 
chromatography. The absence of endotoxin contamination was verified by Limulus assay. 
Recombinant HMGB1 (rHMGB1) in fully-reduced and disulfide redox-state (HMGBiotech) 
was injected intraperitoneally (one bolus: 5 µg of each redox form (in total 10 µg) in a final 
volume of 100 µl PBS).  
Bromodeoxyuridine  (BrdU): BrdU (BD Pharmingen) was administered using osmotic mini-
pumps implanted subcutaneously (Alzet model 1002) at a dose of 50μg/d for one week. 
Osmotic pumps were implanted immediately after stroke or sham surgery.  
Qtracker 655: Qtracker 655 (Life technologies) was injected with a 10 µl microsyringe 
(Hamilton) directly into the femoral bone marrow at the corpus femoris 2 h before stroke or 
sham surgery at a total volume of 2 µl. Administration of sterile PBS was used as a control.  
Adoptive myeloid cell transfer. Donor animals (CCR2 RFP/+ or CCR2 RFP/RFP) were sacrificed 
and hind limbs were collected in Dulbecco's Modified Eagle Medium (DMEM). The muscle 
tissue was removed with 70 % ethanol in a petri dish. The bone marrow was flushed out of 
femur and tibia with DMEM using a syringe and the cell suspension was filtered through 40 
µm cell strainers. After cells were washed and counted they were intraperitoneally injected in 
ApoE–/– recipient mice (107 cells per mouse) in a total volume of 200µl in saline.  
Molecular MRI imaging with VCAM-1-targeted micron-sized iron oxide particles 
(MPIOs). MRI Experiments were carried out on a Pharmascan 7 T/12 cm system using 
surface coils (Bruker, Germany). Before imaging, the mice received an intravenous injection 
of 1 mg/kg of VCAM-1 targeted MPIOs through a tail vein catheter, as previously described 
(22). Thirty minutes thereafter, 3D T2*-weighted gradient echo imaging with flow 
compensation (GEFC, spatial resolution of 93μm x 70μm x 70μm interpolated to an isotropic 
resolution of 70 μm) using respiratory and cardiac gating (images were acquired during the 
end diastole), with TE/TR 6.2ms/~200ms and a flip angle (FA) of 20° was performed to 
visualize MPIOs bound to the aortic valve (acquisition time=8-15 min). During MRI, the 
mice were maintained under anesthesia with 2% isoflurane in 100% O2. For image analysis, 
the first step was to crop the initial MRI in a 70x70 pixels picture, including the aortic valve 
and the surrounding blood. Then, 3D Otsu automated threshold was applied using ImageJ 
software and the signal void volume was computed in mm3. 
Organ and tissue processing. Mice were deeply anaesthetized with ketamine (120 mg/kg) 
and xylazine (16 mg/kg) and venous blood was drawn via cardiac puncture of the right 
ventricle in 50mM EDTA (Sigma-Aldrich); the plasma was isolated by centrifugation at 3000 
relative centrifugal force (rcf) for 10min and stored at -80 °C until further use. The blood 
pellet was resuspended in DMEM and erythrocytes were lysed using isotonic ammonium 
chloride buffer. Mice were then transcardially perfused with normal saline and aorta, heart, 
femurs and spleen were dissected. Spleen and femurs were transferred to Hank’s balanced salt 
solution, homogenized and filtered through 40 µm cell strainers. Erythrocytes in spleens were 
lysed using isotonic ammonium chloride buffer. 
To isolate mononuclear cells from aorta, the whole aorta was minced into small pieces and 
incubated in Roswell Park Memorial Institute (RPMI) medium containing 125 U/ml 
collagenase XI, 60 U/ml hyaluronidase I, 60 U/ml DNase I and 450 U/ml collagenase I 
(Sigma Aldrich) for 30min at 37 °C (44). The cell suspensions were then mechanically 
homogenized, filtered and washed prior to flow cytometry. 
Infarct volumetry. Mice were sacrificed by over dose of ketamine-xylazine and perfused 
intracardially with 10 mL saline solution.  Brains were removed and immediately frozen in 
powdered dry ice. Afterwards, brains were fixed in optimum cutting temperature compound 
(O.C.T., Tissue-tek) solution and 20μm coronal sections were cut on every 400μm. Sections 
were stained with cresyl violet and scanned at 600 dpi. Infarct area on each section was 
analyzed by ImageJ software (NIH). The Swanson method was applied to indirectly measure 
the infarct area and to correct for cortical swelling: [ischemic area] = [area of the contralateral 
hemisphere] - [nonischemic area of the ipsilateral hemisphere]. The total infarct volume was 
determined by integrating measured areas and distances between sections. 
Monocyte activation assay. Splenic monocytes were isolated using CD11b+ magnetic-
activated cell sorting (CD11b Micro beads, Miltenyi) and cultured (DMEM, 10 % FCS, 1 % 
Penicilin/Streptavidin) in 12-well flat-bottom plates (5x105 cells per well). Purity of monocyte 
Magnetic-activated cell sorting isolation was verified by flow cytometric analysis to be ≥ 95 
%. Treatment with rHMGB1 (0.1 and 0.5 µg/ml), murine stroke or sham plasma (50 % in 
DMEM) was given in each well individually and 4 h later cells were harvested and prepared 
for further analysis.  
In vitro murine aortic endothelium stimulation assay. Murine aortic endothelial cells 
(Innoprot, Ref: P10427) were seeded in fibronectin-coated 12-well flat-bottom plates (5x105 
cells per well, Basal medium, 5 % FCS and 1 % Penicillin/Streptavidin, 1 % endothelial cell 
growth supplement) overnight. Cells were starved for 4 h (basal medium, 1 % 
Penicillin/Streptavidin) and before they received treatment (recombinant TNF-α: 20 ng/ml, 
plasma: 50 % in DMEM, recombinant HMGB1: 0.5 µg/ml). The plasma used to stimulate 
MAECs was collected from stroke- or sham-operated mice 4 h post-lesion. After a 4 h 
stimulation interval, cells were trypsinized, harvested, washed in PBS and stored at -20°C 
until further analysis. 
Flow cytometry analysis. The following anti-mouse antibodies were used for cell stainings: 
anti-CD3 (clone: 17A2, eBioscience), anti-CD4 (clone: RM4-5, eBioscience), anti-CD45 
(clone: 30-F11, eBioscience), anti-CD11b (clone: M1/70, eBioscience), anti-CD11c (clone: 
HL3, eBioscience), anti-Ly6C (clone: HK1.4, eBioscience), anti-Ly6G (clone: RB6-8C5, 
eBioscience), anti-MHC class II (clone: NIMR-4, eBioscience), anti-CCR2 (clone: 
FAB5538A, R&D systems), BrdU (clone: MOPC-21, BD Biosciences). Stainings were 
performed according to the manufacturer’s protocols. Flow cytometric data was aquired on a 
BD FACSverse flow cytometer (BD Biosciences) and analyzed using FlowJo software 
(Treestar). 
Oil Red O lipid staining. For whole aorta en face stainings, aortas were carefully dissected 
and adventitial fat was thoroughly trimmed away. Aortas then were cut open, unfolded, and 
pinned out on a silicon-elastomer for fixation in 4% paraformaldehyde (PFA) at 4 °C 
overnight. The aortas then were washed for 4 h in PBS, afterwards placed in 100 % propylene 
glycol for 2 min at 25 °C and finally transferred to 0.5 % Oil Red O for 3 h at 25 °C. Then 
aortas were washed in 85 % propylene glycol and stored in PBS until image acquisition (45). 
For lipid stainings of aortic valve sections, the ventricles were removed horizontally from 
dissected hearts, embedded in O.C.T compound (Tissue Tek) and consecutively 
cryosectioned. Sections were dried, post-fixed in 4 % PFA and stained after dehydration for 1 
h in 0.5 % Oil Red O solution at 37 °C. Finally, sections were counterstained for nuclei with 
Mayer’s Hematoxylin, air dried and mounted with pre-warmed gelatin (45). For lipid staining 
of the common carotid artery branches, the carotid bifurcation area was dissected and 
embedded in OCT. compound. After consecutive sectioning, lipid depositions were stained 
with the same Oil Red O staining protocol as stated above. 
Quantification of cap thickness and plaque rupture. Aortic valve sections stained with Oil 
Red O and Hematoxylin were microphotographed and cap thickness was assessed. Three to 
five measurements representing the thinnest part of the cap were averaged for each plaque 
(46). Acute plaque rupture was accepted when a visible defect in the cap was accompanied by 
intrusion of erythrocytes in the plaque. In some animals, 1 or more buried fibrous caps were 
seen within the body of plaque which were also counted as a plaque rupture (16). 
MMP 2 and 9 in situ zymography of aortic valve sections. DQ-gelatin (D12054, 
Invitrogen) was dissolved in reaction buffer (50 mM Tris-HCl, 150 mM NaCl, 5 mM CaCl2, 
200 mM sodium azide, pH 7.6). Cryosections were incubated for 3 h at 37 °C with the 
gelatin-containing reaction buffer. Negative control sections were pre-incubated for 1 h with 
the MMP-inhibitor 1,10-Phenathroline (Sigma). Nuclei were stained with DAPI. MMP 
activity was detected on an Axio Observer Z1 microscope with 10x magnification and a 
Fluorescein isothiocyanate (FITC) filter (Carl Zeiss). Data were expressed as 
MMP+ area(µm²) and normalized MMP intensity (Normalized MMP intensity = Integrated 
Density – (Selected valve Area x Background mean fluorescence). 
Tyrosine hydroxylase (TH) stainings. Dissected femurs (see above) were decalcified in 0,4 
M ethylenediaminetetraacetic acid (EDTA, pH 7.4) for 72 hours. Femurs then were embedded 
in OCT compound (Tissue Tek) and consecutively sectioned. Sections were blocked with 10 
% goat serum and 1 % bovine serum albumin (BSA) for 2 h. After washing with 0,025 % 
Triton X-100 in TBS, sections were incubated with an antibody against TH (rabbit, abcam) 
overnight at 4 °C. After washing, sections were then incubated with secondary antibody 
against rabbit (alexa-647, goat, DAKO) for 90 min at room temperature. Nuclei were stained 
with DAPI. Pictures were acquired with a confocal microscope at 40x magnification (LSM 
880 Carl Zeiss). 
Enzyme linked immunosorbent assay. HMGB1 levels were measured from diluted plasma 
samples (1:10) using a commercial assay kit according to the manufacturer's instructions (IBL 
international, Hamburg). For CCL-2 levels diluted samples (1:10) were measured using an 
ELISA kit according to a standard protocol (eBioscience). 
Quantitative real time PCR (RT-PCR). Total RNA was purified from aorta, spleen, murine 
aortic endothelial cells (MAECs) and isolated monocytes using a RNeasy Mini Kit (Qiagen). 
Equal amount of RNA from each sample was used for cDNA synthesis using High Capacity 
cDNA Reverse Transcription Kit (Applied Biosystems). The quantitative expression of 
different cytokines was measured by quantitative real-time PCR with the LightCycler 480 II 
(Roche) and RT2 qPCR Primer Assays and SYBR Green ROX qPCR Mastermix (Qiagen).  
Primer sequences: 
IL-1β: forward  ‘5-ACAGATGAAGTGCTCCTTCCA-3’, reverse ‘5-
GTCGGAGATTCGTAGCTGGAT-3’ 
IL-6: forward ‘5-CAGTTGCCTTCTTGGGACTGA-3’, reverse ‘5-
GGGAGTGGTATCCTCTGTGAAGTCT-3’ 
TNF-α: forward 5'-CAT CTT CTC AAA ATT CGA GTG ACA A-3', reverse5'-TGG GAG 
TAG ACA AGG TAC AAC CC-3' 
IFN-γ: forward 5’-TGGCATAGATGTGGAAGAAAAGAG-3’, reverse 5’-
TGCAGGATTTTCATGTCACCAT-3’ 
ICAM-1: forward 5′-CAATTTCTCATGCCGCACAG-3′, reverse 5′-
AGCTGGAAGATCGAAAGTCCG-3′ 
VCAM-1: forward 5′-TGAACCCAAACAGAGGCAGAGT-3′, reverse 5′- 
GGTATCCCATCACTTGAGCAGG-3’ 
RAGE: forward 5´-GGACCCTTAGCTGGCACTTAGA-3´, reverse5´-
GAGTCCCGTCTCAGGGTGTCT-3´ 
PPIA: forward ‘5-ACGCCACTGTCGCTTTTC-3’, reverse ‘5-
ACCCGACCTCGAAGGAGA-3’ 
GAPDH: forward 5’-TGACGTGCCGCCTGGAGAAA-3’, reverse 5’-
AGTGTAGCCCAAGATGCCCTTCAG-3’ 
RT-PCR array. The RT2 PreAMP cDNA syntesis Kit (Qiagen) was used for the cDNA 
synthesis and RT2 Profiler PCR Array for chemokines and chemokine receptors (PAMM-
022Z, Qiagen) was measured in a Roche LightCycler 480. Finally, data was analyzed with 
RT2 Profiler PCR Array Data analysis software (version3.5) from SABiosciences. 
Quantification of patient infarct volumes. Infarct volumes were quantified on images from 
diagnostic scans, either computed tomography or magnetic resonance imaging (diffusion-
weighted, T2 or fluid-attenuated inversion recovery). The modality and image with the largest 
infarct size was used for volumetry. Trained raters segmented infarcts manually slice-by-slice. 
The inter-rater reliability for this procedure showed an intraclass correlation coefficient of 
0.993. 
Analysis of HMGB1 isoforms by electrospray ionization liquid chromatography tandem 
mass spectrometry (ESI-LC-MS/MS). Samples were pre-cleared with 50 µl protein G-
Sepharose beads for 1h at 4°C and HMGB1 present was immunoprecipitated with 5 µg of 
rabbit anti-HMGB1 (ab18256) for 16 h at 4°C as previously described (47). For the analysis 
of HMGB1 post translational modifications, free thiol groups within HMGB1 were alkylated 
for 90 min with 10 mM iodoacetamide at 4°C. Cysteine residues in disulfide bonds were then 
reduced with 30 mM dithiothreitol at 4°C for 1 h followed by alkylation of newly exposed 
thiol groups with 90 mM NEM at 4°C for 10 min as previously described (33, 48). Samples 
were subjected to trypsin (Promega) or GluC (New England Biolabs) digestion according to 
manufacturer’s instructions and de-salted using C18 zip-tips (Millipore). Characterization of 
post translational modifications within HMGB1 were determined as described previously 
using an AB Sciex QTRAP 5500 (Sciex Inc.) equipped with a NanoSpray II source by in-line 
liquid chromatography using a U3000 HPLC System (Dionex), connected to a 180 µm x 20 
mm nanoAcquity UPLC C18 trap column and a 75 µm x 15 cm nanoAcquity UPLC BEH130 
C18 column (Waters) via reducing unions. A gradient from 0.05% TFA (v/v) to 50% 
ACN/0.08% TFA (v/v) in 40 min was applied at a flow rate of 200 nL/min (49). The ion 
spray potential was set to 2,200-3,500 V, the nebulizer gas to 19 L/min and the interface 
heater to 150°C. Accurate mass and whole protein electrospray ionisation (ESI) mass 
spectrometry is determine as previously described using a AB Sciex TripleToF 5600+ system 
(49). 
  
Supplementary Figures 
 
Figure S1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S1. Characterization of the 60-min filament MCA occlusion (fMCAo) model. (A) 
Coronal brain sections from T2w MRI of an in infarcted brain 5 days after 60 min fMCAo 
surgery. (B) Cresyl violet histology of coronal sections of an infarcted brain 7 days after 
fMCAo. (C) Quantification of brain infarct volume cresyl violet histology of a untreated 
compared to anti-HMGB1 antibody and sRAGE treated brains. (D) Comparison of stroke 
assessment scores 1 h after reperfusion in fMCAo mice (n= 6-16 per group). All mice used 
are HCD-fed ApoE−/− mice. 
 
Figure S2 
Figure S2. Exacerbation of atherosclerotic lesions in aortic valves of male and female 
HCD-fed ApoE−/− mice 1 month after fMCAo surgery. (A) Representative images of Oil 
Red O aortic valve quantification of female HCD-fed ApoE−/− mice one month after stroke or 
sham surgery. (B) Plaque area quantification of 5 consecutive levels in aortic valves (left) and 
area under curve (AUC, right) analysis in stroke and sham-operated mice one month after 
surgery (U Test, 8-10 per group). All data in panel B are shown as mean with error bars 
indicating s.d. 
 
 
Figure S3 
 
Figure S3. Immune cell counts in aorta of HCD-fed ApoE−/− mice 1 month after 
experimental stroke. (A) CD45+Ly6G+ granulocytes (left) and CD45+CD3+ T cells (right) 
cell counts after sham or stroke surgery. (B) Percentage of CD69+ (left) and CD25+ (right) T 
cell subsets after sham or stroke surgery. (U Test, n= 8-10 per group). 
 
 
Figure S4 
Figure S4. Analysis of atherosclerotic plaque load at the common carotid artery 
bifurcation in HCD-fed ApoE−/− mice. (A) Representative microphotographs of the common 
carotid artery bifurcation on the contralateral side 7 days after stroke or sham surgery (scale 
bar = 1mm, * indicates bifurcation). (B) Representative Oil Red O stained longitudinal 
common carotid artery bifurcation sections (scale bar = 500µm, * indicates bifurcation). (C) 
Quantification of Oil Red O+ plaque load in the contralateral common carotid artery lumen 7 
days after stroke or sham surgery (U Test, n= 5-6 per group). CCA = common carotid artery, 
ICA = internal carotid artery, ECA = external carotid artery. 
 
 
Figure S5 
Figure S5. Comparison of BrdU incorporation in aorta, blood, and spleen 1 week after 
experimental stroke surgery. (A) Percentage of BrdU+ CD3+ T cells (left) and BrdU+ CD19+ 
B cells in aorta after stroke or sham surgery. (B, C) Percentage of BrdU+ cells in blood (B) 
and spleen (C) after experimental stroke or sham surgery (U Test, n= 6-8 mice per group). All 
bar graphs are shown as mean ± s.d. 
 
Figure S6 
 
Figure S6. RFP+CD11b+ cell counts in blood after experimental stroke surgery. HCD-fed 
ApoE–/– mice underwent sham or stroke surgery received CCR2RFP/+ bone marrow cell 
(BMC) transplantation (107 cells) immediately after surgery. One week later mice were 
sacrificed and blood analyzed. (A) Flow cytometric gating strategy to analyze RFP+CD11b+ 
cells in blood. (B) Quantification of total RFP+CD11b+ cell counts in blood one week after 
sham or stroke surgery (left). Percentage of RFP+CD11b+ cells in blood one week after sham 
or stroke surgery (right, U Test, n= 5-6 mice per group). All bar graphs are shown as mean ± 
s.d. 
 
Figure S7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S7. Immunological data of stroke patients. (A) Comparison of hs-CRP and 
leukocyte subpopulations between HCs and patients with IS at day 2 (Wilcoxon rank sum 
test) (B) Regression of total HMGB1 levels with hs-CRP or monocytes/nl of HCs and IS 
patients at day 2 after stroke (Linear regression analysis with adjustment for groups). (C) 
Regression analysis of NIHSS scores and total HMGB1 levels in patients with IS from 
admission to day 7 after stroke (Linear mixed model with day as random effect). 
Abbreviations: NIHSS, National Institute of Health stroke scale; IS, ischemic stroke. 
Figure S8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S8. Body weight and mortality in sRAGE treatment mice after stroke. (A) Body 
weight curves (left, indicated as % body weight to individual baseline before stroke) after 
sham and stroke surgery with vehicle or sRAGE treatment. Area under curve analysis (right) 
for statistical analysis of indicated groups (U Test, n= 10-15 mice per group, graphs shown as 
mean ± s.d.). (B) Kaplan-Meier curves of post-stroke survival within one month after stroke 
in vehicle or sRAGE treated and sham-operated mice (Comparison of differences between 
curves by Mantel-Cox Test , n= 28-47). 
 
 
Figure S9 
 
Figure S9. Atherosclerotic lesions in aortic valves of male and female HCD-fed ApoE−/− 
mice 1 month after experimental stroke and sRAGE treatment. (A) Representative 
images of Oil Red O aortic valve sections of male and female HCD-fed ApoE−/− mice with 
vehicle or sRAGE treatment 4 weeks after stroke surgery. (B) Plaque area quantification of 5 
consecutive levels in aortic valves and area under curve (AUC) analysis of stroke (± sRAGE) 
for male and female mice (U Test, n= 8-10 mice per group). All graphs are shown as mean 
with error bars indicating s.d. 
 
 
Figure S10 
 
Figure S10. Lipid profile of plasma samples 1 month after experimental stroke surgery 
and sRAGE treatment. Triglycerides, cholesterol, cholinesterase, urea, lactate 
dehydrogenase (LDH), glutamate dehydrogenase (GLDH), aspartate aminotransferase (AST) 
and glutamic pyruvic transaminase (GPT) concentrations after experimental stroke or sham 
surgery (± sRAGE) in HCD-fed ApoE−/− mice. (One way-ANOVA; n= 8-9 mice per group). 
All bar graphs are shown as mean ± s.d. 
 
Figure S11 
 
Figure S11. Flow cytometric analysis of spleen and blood 24 hours after experimental 
stroke with anti-HMGB1 treatment. (A) Flow cytometric analysis of WT mice treated with 
IgG control or HMGB1-specific monoclonal antibodies (anti-HMGB1) 24 h after stroke 
surgery. Whole CD45+ spleen cell counts (left) and percentages of CD11b+ (middle) and 
CD11b+MHCII+ (right) cells were measured. (B) Flow cytometric analysis of CD45+CD11b+ 
(left), CD11b+CCR2+ (middle) and CD11b+MHCII+  (right) cell percentages from blood 24 h 
after stroke ± anti-HMGB1 treatment (U Test, n= 5-8 mice per group). All bar graphs are 
shown as mean ± s.d. 
 
 
Figure S12 
 
Figure S12. Recombinant HMGB1 in vivo administration exacerbates atherosclerosis. 
HCD-fed ApoE−/− mice received i.p. injection of a single bolus of 10 µg rHMGB1. After one 
week mice were sacrificed and aorta and aortic valve were analyzed. Expression of Il-6 (left), 
Icam-1 (middle) and Vcam-1 (right) (RE, relative expression) was analyzed from aorta lysates 
(U Test, n= 5 per group). All graphs are shown as mean ± s.d. 
 
 
Figure S13 
 
Figure S13. Quantification of in vivo Qdot labeling of femoral bone marrow 24 hours 
after experimental stroke. WT mice received Qdot administration in the femoral bone 
marrow 2h before sham or stroke surgery and were sacrificed 24 h later. (A) Representative 
gating strategy for CD45+CD11b+ monocytes and Qdot+ monocytes in femoral bone marrow 
after stroke or sham surgery. (B) Quantification of myeloid cells (left) and Qdot+ monocytes 
(right) in femoral bone marrow (U Test, n= 6 per group). All graphs are shown as mean ± s.d. 
 
 
Figure S14 
 
Figure S14. Myeloid cell count in femoral bone marrow and brain infarct volumetry 
after splenectomy. Spleen of HCD-fed ApoE−/− mice were removed surgically or sham 
surgery was performed before experimental stroke was induced. One week later mice were 
sacrificed and analyzed for myeloid cell counts and infarct volumetry. (A) Flow cytometric 
analysis of bone marrow from either splenectomized or sham operated mice after 
experimental stroke (U Test, n= 6-8 per group). (B) Cresyl violet histology of infarcted brains 
from stroked mice with either splenectomy or sham surgery (U Test, n=6 per group). All 
graphs shown as mean ± s.d. 
 
 
Figure S15 
 
Figure S15. Impact of β3-adrenoreceptor blockage on HMGB1 plasma levels after 
experimental stroke. HMGB1 plasma concentrations were measured by ELISA in sham and 
stroke-operated (± SR59230A treatment) HCD-fed ApoE−/− mice 7d after surgery (H Test, n= 
6-8 per group). Graph is shown as mean ± s.d. (* = p value <0.05). 
 
 
Figure S16 
 
Figure S16. Impact of β3-adrenoreceptor blockage (SR59230A), alarmin blockage 
(sRAGE), and combined treatment on blood immune cells in WT mice. WT mice 
received either SR59230A, sRAGE, both combined or control treatment immediately after 
stroke and blood was analyzed by flow cytometry 24 h later for total myeloid 
(CD45+CD11b+), CD11b+Ly6Chigh, MHCII and CCR2 expressing cells (H Test, n= 6-8 per 
group). All graphs are shown as mean ± s.d. (*: p <0.05) 
 
 
Figure S17 
 
Figure S17. Schematic overview of proposed mechanism of atheroprogression after 
stroke. 
  
Table S1. Primer list for quantitative PCR array (mouse chemokines and receptors). 
Symbol Description 
C5ar1 Complement component 5a receptor 1 
Ackr2 Chemokine binding protein 2 
Ccl1 Chemokine (C-C motif) ligand 1 
Ccl11 Chemokine (C-C motif) ligand 11 
Ccl12 Chemokine (C-C motif) ligand 12 
Ccl17 Chemokine (C-C motif) ligand 17 
Ccl19 Chemokine (C-C motif) ligand 19 
Ccl2 Chemokine (C-C motif) ligand 2 
Ccl20 Chemokine (C-C motif) ligand 20 
Ccl22 Chemokine (C-C motif) ligand 22 
Ccl24 Chemokine (C-C motif) ligand 24 
Ccl25 Chemokine (C-C motif) ligand 25 
Ccl26 Chemokine (C-C motif) ligand 26 
Ccl28 Chemokine (C-C motif) ligand 28 
Ccl3 Chemokine (C-C motif) ligand 3 
Ccl4 Chemokine (C-C motif) ligand 4 
Ccl5 Chemokine (C-C motif) ligand 5 
Ccl6 Chemokine (C-C motif) ligand 6 
Ccl7 Chemokine (C-C motif) ligand 7 
Ccl8 Chemokine (C-C motif) ligand 8 
Ccl9 Chemokine (C-C motif) ligand 9 
Ccr1 Chemokine (C-C motif) receptor 1 
Ccr10 Chemokine (C-C motif) receptor 10 
Ccr1l1 Chemokine (C-C motif) receptor 1-like 1 
Ccr2 Chemokine (C-C motif) receptor 2 
Ccr3 Chemokine (C-C motif) receptor 3 
Ccr4 Chemokine (C-C motif) receptor 4 
Ccr5 Chemokine (C-C motif) receptor 5 
Ccr6 Chemokine (C-C motif) receptor 6 
Ccr7 Chemokine (C-C motif) receptor 7 
Ccr8 Chemokine (C-C motif) receptor 8 
Ccr9 Chemokine (C-C motif) receptor 9 
Ackr4 Chemokine (C-C motif) receptor-like 1 
Ccrl2 Chemokine (C-C motif) receptor-like 2 
Cmklr1 Chemokine-like receptor 1 
Cmtm2a CKLF-like MARVEL transmembrane domain containing 2A 
Cmtm3 CKLF-like MARVEL transmembrane domain containing 3 
Cmtm4 CKLF-like MARVEL transmembrane domain containing 4 
Cmtm5 CKLF-like MARVEL transmembrane domain containing 5 
Cmtm6 CKLF-like MARVEL transmembrane domain containing 6 
Cx3cl1 Chemokine (C-X3-C motif) ligand 1 
Cx3cr1 Chemokine (C-X3-C) receptor 1 
Cxcl1 Chemokine (C-X-C motif) ligand 1 
Cxcl10 Chemokine (C-X-C motif) ligand 10 
Cxcl11 Chemokine (C-X-C motif) ligand 11 
Cxcl12 Chemokine (C-X-C motif) ligand 12 
Cxcl13 Chemokine (C-X-C motif) ligand 13 
Cxcl14 Chemokine (C-X-C motif) ligand 14 
Cxcl15 Chemokine (C-X-C motif) ligand 15 
Cxcl16 Chemokine (C-X-C motif) ligand 16 
Cxcl2 Chemokine (C-X-C motif) ligand 2 
Cxcl3 Chemokine (C-X-C motif) ligand 3 
Cxcl5 Chemokine (C-X-C motif) ligand 5 
Cxcl9 Chemokine (C-X-C motif) ligand 9 
Cxcr1 Chemokine (C-X-C motif) receptor 1 
Cxcr2 Chemokine (C-X-C motif) receptor 2 
Cxcr3 Chemokine (C-X-C motif) receptor 3 
Cxcr4 Chemokine (C-X-C motif) receptor 4 
Cxcr5 Chemokine (C-X-C motif) receptor 5 
Cxcr6 Chemokine (C-X-C motif) receptor 6 
Ackr3 Chemokine (C-X-C motif) receptor 7 
Ackr1 Duffy blood group, chemokine receptor 
Fpr1 Formyl peptide receptor 1 
Gpr17 G protein-coupled receptor 17 
Hif1a Hypoxia inducible factor 1, alpha subunit 
Ifng Interferon gamma 
Il16 Interleukin 16 
Il1b Interleukin 1 beta 
Il4 Interleukin 4 
Il6 Interleukin 6 
Itgam Integrin alpha M 
Itgb2 Integrin beta 2 
Mapk1 Mitogen-activated protein kinase 1 
Mapk14 Mitogen-activated protein kinase 14 
Pf4 Platelet factor 4 
Ppbp Pro-platelet basic protein 
Slit2 Slit homolog 2 (Drosophila) 
Tgfb1 Transforming growth factor, beta 1 
Tlr2 Toll-like receptor 2 
Tlr4 Toll-like receptor 4 
Tnf Tumor necrosis factor 
Tymp Thymidine phosphorylase 
Xcl1 Chemokine (C motif) ligand 1 
Xcr1 Chemokine (C motif) receptor 1 
Actb Actin, beta 
B2m Beta-2 microglobulin 
Gapdh Glyceraldehyde-3-phosphate dehydrogenase 
Gusb Glucuronidase, beta 
Hsp90ab1 Heat shock protein 90 alpha (cytosolic), class B member 1 
 
  
Table S2. Demographic and clinical characteristics of the study population. 
Characteristics Stroke Control 
Demographic characteristics   
     Total, n 18 12 
     Age, mean (SD) [years] 72.7 (14.3) 72.1 (5.9) 
     Female, n (%) 7 (38.9) 8 (66.7) 
Vascular risk factors, n (%)   
     Hypertension 15 (83.3) 4 (33.3) 
     Smoking history 8 (47.1) 3 (25) 
     Hypercholesterolemia 2 (11.8) 1 (8.3) 
     Obesity 4 (26.7) 1 (8.3) 
     Diabetes mellitus  1 (5.6) 0 (0) 
     Previous TIA/stroke/MI 5 (27.8) 0 (0) 
ΔT, mean (SD) [hours] 5.5 (5.6) n/a 
Infarct volumes, mean (SD) [ml] 74.4 (48.0) n/a 
SD, standard deviation; TIA, transient ischemic attack; MI, myocardial infarction; ΔT, time from symptom onset 
until hospital arrival; n/a, not available. 
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